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ABSTRACT
Pancreatic cancer is the fourth leading cause of cancer mortality with a five-year
survival rate of less than 5 %. It shows no symptoms until it has reached an advanced
stage upon which it has metastasized to distant organs limiting therapeutic options.
Several studies have identified smoking, alcohol, diabetes and pancreatitis as risk factors
for pancreatic cancer. While smoking is a well-documented risk factor for this
malignancy, there still remains a controversy on whether alcohol can act as a risk factor
itself or cooperatively enhances the effects of other risk factors.
Previous reports provide evidence that nicotinic acetylcholine receptors (nAChRs)
and beta-adrenergic receptors cooperatively stimulate the growth and migration of normal
and pancreatic ductal adenocarcinoma (PDAC) cells upon binding NNK. Binding of the
nicotine-derived nitrosamine ketone (NNK) to nAChRs result in neurotransmitters
production regulation. These neurotransmitters in turn act as agonists to β-ARs [betaadrenergic receptors] thereby activating adenylyl cyclase and the subsequent cAMP
dependent signaling pathways. This ultimately results in the stimulation of proliferation,
migration and angiogenesis and inhibition of apoptosis.
Using assays for the assessment of adrenaline, noradrenaline, GABA and cAMP
production; PKA activity; CREB, Src, Akt and ERK phosphorylation; and cell
proliferation and migration, we have identified an autocrine catecholamine loop that is
jointly regulated by α3, 5 and 7-nAChRs [alpha 3, 5 and 7-nicotinic acetylcholine
receptors] in normal pancreatic ductal epithelial cells (HPDE6-C7) and PDAC cell lines
(BxPC-3 and Panc-1) upon stimulation by nicotine or ethanol. This catecholamine loop in
vi

turn acts to stimulate growth of normal and PDAC cell lines via cAMP dependent
signaling pathways downstream β-ARs [beta-adrenergic receptors]. This loop however,
is interrupted upon γ-amino butyric acid [gamma-amino butyric acid] (GABA) treatment
of cells at the level of adenylyl cyclase activation thereby inhibiting nicotine and ethanolinduced stimulatory effects on cell proliferating and migration.
Our study findings therefore suggest smoking and chronic alcohol intake to be
risk factors for the development of PDAC. These agents regulate catecholamine and
GABA synthesis via modulation of nAChRs thereby stimulating proliferation and
migration and inhibiting apoptosis. The observed effects of nicotine and ethanol were all
reversed by treatment of cells with GABA, suggesting it as a potential therapeutic agent
for the treatment and prevention of this malignancy.
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CHAPTER I:
Introduction

1

Introduction
The pancreas is a fish shaped organ behind the stomach that is composed of two
different glands [1]. The exocrine gland makes up the larger portion of the pancreas and
is responsible for the production of the pancreatic juice which contains enzymes
necessary for the digestion of fats and proteins found in food. On the other hand, a small
portion of the pancreas composed of islet cells makeup the endocrine gland which is
responsible for the secretion of hormones mainly involved in blood glucose regulation [13].
Tumors of the pancreas can rise in both the exocrine and endocrine glands. However,
most tumors formed in the pancreas are of exocrine origin and are mostly referred to as
adenocarcinomas [1,4]. Pancreatic cancer is one of the most aggressive diseases, ranking
fourth in cancer mortality in western countries [5,6]. Pancreatic ductal adenocarcinoma
(PDAC) make up the majority of pancreatic cancer compromising more than 90 % of all
cases [6-8]. Studies have shown that PDAC has a poor five-year survival rate of less than
5 % and morality rate near 100 % within two years of diagnosis [4,6,9,10]. Studies on
pancreatic cancer show 265, 000 deaths out of 280, 000 cases in 2008; while estimates by
the American Cancer Society predict more than 43,920 new cases and 37,390 deaths
from pancreatic cancer in 2012 [11,12].
Several risk factors have been linked to pancreatic cancer. Smoking is a welldocumented risk factor for this malignancy with Smokers having a twofold increase in
the development of PDAC over non-smokers [13]. Other risk factors associated with this
malignancy include chronic alcohol consumption, pancreatitis, diabetes, obesity and
2

family history [14-18]. The major obstacle to effective clinical outcomes for pancreatic
cancer is its delayed diagnosis and resistance to current therapeutics. It shows no
symptoms until it has reached an advanced stage upon which it has metastasized to
distant organs further complicating its treatment [19,20]. Therefore, further research on
pancreatic cancer prevention and therapy are urgently needed.
While older research has focused on gene mutations, recent studies on pancreatic
cancer focus on upstream pathways such as nicotinic acetylcholine receptors (nAChRs)
and their associated neurotransmitters [21]. These receptors are heterogeneous ionotropic
receptors that were initially thought to be restricted to the central nervous system;
however, recent studies found them to be expressed in non-neuronal cells such as in the
pancreas and the lung [21,22]. Activation of these receptors results in several cellular
changes including regulation of the production and secretion of the stimulatory
neurotransmitters adrenaline and noradrenaline and the inhibitory neurotransmitter
GABA [21,23-26].
The catecholamines produced upon activation of these nAChRs result in the
activation of β-adrenergic receptors which are G-protein coupled receptors that activate
adenylyl cyclase via the stimulatory G-protein subunit [21,27,28]. Activation of the
adenylyl cyclase results in an increase in cAMP levels thereby activating several cAMP
dependent pathways which ultimately results in the activation of proliferation and
migration of PDAC cells and their normal cells of origin [21,29-31].
While several studies have been consistent on the effects of adrenaline and
noradrenaline on PDAC cells and their normal cells of origin, research on GABA is still
3

controversial. Some studies have found that binding of GABA to its receptor, GABA-B
results in the inhibition of this catecholamine-induced pathway via the inhibition of the
adenylyl cyclase by the inhibitor G-protein subunit of GABA-B receptor [30]. However,
other studies have found that some PDAC cell lines over-expressed the pi-subunit of
GABA-A receptor. Over-expression of this subunit reverses GABA-A’s role from being
a hyperpolarizing ionotropic receptor to a depolarizing one. Therefore, binding of GABA
to GABA-A receptor results in the depolarization of these cell lines thereby increasing
intracellular calcium levels which ultimately stimulates cell growth in calmodulinCalcium dependent mechanism [32].
Using assays for the assessment of cAMP, GABA, adrenaline and noradrenaline
production; PKA and MAPK activation; Akt, CREB, Src and ERK phosphorylation; and
cell proliferation and migration, this project identified an autocrine catecholamine loop
that is co-regulated by α3, 5 and 7-nAChRs in PDAC cells and their normal cells of
origin. This loop activates multiple cellular pathways downstream β-ARs thereby
stimulating cell proliferation and migration. Moreover, our data shows that PDAC cells
and their normal cells of origin produce GABA via regulation of α4-nAChR and that
treatment of these cells with GABA reverses catecholamine-induced stimulation of
growth and migration.
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Working hypothesis
The central hypothesis of this project is that ethanol and nicotine alone and in
combination promote growth and migration of the immortalized human pancreatic duct
epithelial cells (HPDE6-C7) and PDAC cell lines (BxPC-3 and Panc-1) via regulation of
nAChRs sensitivity and that these effects were reversed via GABA treatments. Data
generated by this project supported this hypothesis and showed that both agents
stimulated growth and migration of these cell lines via activation of cAMP dependent
pathways downstream the nAChRs.

Specific aims
1. To test the hypothesis that nicotine stimulates the growth and migration of PDAC
cells and their normal cells of origin, and to identify its mechanism of action.
2. To test the hypothesis that ethanol stimulates the growth and migration of PDAC
cells and their normal cells of origin, and to identify its mechanism of action.
3. To test the hypothesis that GABA reverses nicotine- and ethanol-induced growth
and migration of PDAC cells and their normal cells of origin, and to identify its
mechanism of action.
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CHAPTER II:
Literature Review
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Abstract
Pancreatic cancer is an aggressive disease with poor diagnosis and prognosis. The
absence of effective screening tests to detect this malignancy at an early stage is one of
the factors responsible for its metastasis. Patients suffering from pancreatic cancer do not
show any symptoms until it has reached an advanced stage upon which it has spread to
distant organs thereby eliminating surgery as a possible option for therapy. Up to date,
there are no effective treatments for pancreatic cancer which makes pancreatic cancer a
deadly disease with a 5 year survival rate of less than 5 %. With these horrifying
statistics, research on pancreatic cancer took a different approach in studying the
mechanisms of this malignancy. While research on the past focused on gene mutations
and their downstream signaling pathways, recently, research started to look at up-stream
receptors such as nicotinic acetylcholine receptors and how they may be involved in
regulating growth of this malignancy.
Nicotinic acetylcholine receptors (nAChRs) are a family of plasma membrane,
ionotropic receptors consisting of five subunits. While these receptors were previously
thought to be restricted to the nervous system, recent studies have found them to be
expressed in most mammalian cells including those of the pancreas. Binding of these
receptors to their agonists result in the activation of their associated ion channels which
results in several cellular changes including neurotransmitters production. Among the
neurotransmitters whose production increase upon activation of the nAChRs are the
catecholamine, adrenaline and noradrenaline.
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These catecholamines act as agonists to beta adrenergic receptors. These receptors
are a family of G-protein coupled receptors which upon activation by adrenaline or
noradrenaline, activate adenylyl cyclase and thereby activating cAMP-dependent
signaling pathways responsible for growth regulation of pancreatic cancer cells.
While research has failed in finding an effective treatment for pancreatic cancer,
recent studies have found the γ-amino butyric acid (GABA) to be an effective anti-cancer
agent in vitro and in vivo. This non-essential amino acid is a nutritional supplement
found in many plants and fruits including tomatoes, berries and rice. Studies have shown
GABA to inhibit pancreatic cancer stimulatory pathways via inhibiting adenylyl cyclase
activation through the inhibitory G protein subunit of GABA-B receptor. This agent,
therefore, may serve as a potential therapeutic option for the prevention and treatment of
pancreatic cancer.

Pancreatic cancer overview
As part of normal growth, cell growth, division and death are governed at several
stages of life to ensure production of healthy and normal individual. Once cells start to
grow out of control, they initiate cancer [1]. Cancer cell growth differs from normal cell
growth in that they continue to grow and divide without any restrictions or limitations
due to the absence of effective control centers [1,2]. Moreover, cancer cells in most cases
form a mass of cells referred to as tumors. However, not all tumors are considered
cancerous. Benign tumors are localized tumors incapable of invading other tissues and
most of the time they can be treated via surgical removal of the tumor. On the other hand,
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some tumors have the ability to spread and invade other tissues, a process referred to as
metastasis. These tumors are referred to as cancers and are considered life threatening
due to the complexity of their treatment [1-4].
There are many different types of cancers all of which start with out of control growth
due to mutations that result in the activation of oncogenes or inactivation of tumor
suppressor genes and DNA repair genes. While the initial stage of cancer is the same,
different kinds of cancers can behave differently in terms of growth and division rate as
well as treatment response [1-4]. Moreover, each type of cancer may have several
subtypes depending on the location and type of cells involved. These subtypes present
further complication to understanding and treating cancer [1]. For example, lung cancer is
divided into four main histological types of cancers: small cell carcinoma, squamous cell
carcinoma, adenocarcinoma and large cell carcinoma. Each of these subtypes show
different mechanism of development that make it distinguished from other subtypes and
is therefore unique in its growth and responsiveness to therapy [5,6].
The pancreas is an interesting organ due to its ability to exert both endocrine and
exocrine functions in the body. The endocrine portion of the pancreas produces and
releases hormones that act as main regulators of blood glucose levels such as insulin,
glucagon and somatostatin. On the other hand, the exocrine gland of the pancreas
produces several enzymes cumulatively referred to as the pancreatic juice that play vital
role in the digestion of ingested food [1]. Tumors in the pancreas can rise from both the
endocrine and exocrine glands. While the tumors rising from islet cells in the endocrine
portion of the pancreas are rare, they tend to be very serious and life threatening. These
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tumors, referred to as neuroendocrine tumors, tend to cause severe changes in hormonal
production and secretion which cause significant changes in blood glucose levels [1]. On
the other hand, tumors rising from the exocrine glands make the majority of pancreatic
cancer cases [1,2,4]. The majority of exocrine tumors are adenocarcinomas that rise from
glandular cells. Over 75 % of pancreatic cancer cases are adenocarcinomas derived from
ductal and ductal epithelia and are referred to as pancreatic duct adenocarcinoma (PDAC)
[7]. Another type of exocrine tumor is the ampullary cancer which rises in the space
where the bile and pancreatic ducts empty into the small intestines. Treatment of all of
these exocrine tumors is usually based on the stage of cancer not its exact type. The
earlier the stage, the better the chance of tumor removal via surgical interference;
however, later stage tend to be more responsive to chemo and/or radiotherapy [1-3].
Epidemiological studies rank pancreatic cancer as the fourth leading cause of cancer
death in the world with a morality rate near 100 % within two years of diagnosis [8-10].
It is responsible for the death of 265,000 patients worldwide in 2008 [3,11,12]. Within
the past 25 years, pancreatic cancer has a median survival of six months and a five year
survival rate of less than 5 % [8,10]. Surprisingly, these studies also show higher rates of
pancreatic cancer incidence and mortality in high income areas compared to low income
regions [3]. Pancreatic cancer morality in high income countries such as Europe and the
U.S has been increasing between 1950s and 80s but has leveled off thereafter in men.
Since the 1980s, incidence of pancreatic cancer in men in Europe leveled off at
7.5/100,000 cases while incidence in women rose to 5/100,000 by the early 2000s
[3,13,14]. Similar trends were seen in the U.S with morality rates stabilizing in men since
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the 1970s and rising in women as time progresses [3,15]. Recent estimates for pancreatic
cancer in the United States show 43,920 new cases and 37,390 deaths from pancreatic
cancer in 2012 [1].
The normal lifetime risk of developing pancreatic cancer for both men and women in
the United States is about 1 in 71 [1]. However, this risk changes upon exposure to risk
factors associated with the development of this malignancy. Several risk factors
associated with pancreatic cancer include smoking, chronic and hereditary pancreatitis,
alcoholism, diabetes and familial cancer syndromes [16-19]. Moreover, while there
appears to be no major gender differences with respect to pancreatic cancer incidence,
reports show African Americans and older people (over the age of 55) to have higher
rates of pancreatic cancer than Caucasians and younger individuals [1].
The aggressive nature of pancreatic cancer lays in its ability to rapidly disseminate to
the lymphatic system and distant organs [20,21]. It does not show any symptoms until it
has reached and advanced stage upon which it has already metastasized to distant organs
[22-24]. The presence of metastasis at the time of diagnosis along with the lack of
effective screening methods and effective chemotherapy contribute to the high mortality
rate in pancreatic cancer patients [20,21]. Pancreatic cancer is one of the most
unresponsive cancers to current therapeutics causing major failure in its treatment
[20,21]. Several standard chemotherapeutics have been clinically established such as
gemcitabine and FOLFIRINOX for the treatment of pancreatic cancer; however, they
only present very minimal increase in survival rate and are not much effective [20,21,25].
Thus, there is no guaranteed way of treating or preventing pancreatic cancer. However,
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one can only minimize their risk of developing pancreatic cancer by avoiding exposure to
risk factors associated with this disease such as smoking and drinking.

Nicotinic acetylcholine receptors
Nicotinic acetylcholine receptors (nAChRs) are a family of ion channels located in
the plasma membrane [26]. These pentameric receptors can be either homomeric
consisting of the same five subunits as in the case of α3, α5, α7, α8 or α9-nAChRs or
heteromeric consisting of combination of subunits from α, β, γ and ε as in the case of
α4β2-nAChR [26-30]. Binding of these nAChRs to their agonists causes conformational
changes in their subunits opening the receptor ion channels. Opening of the ion channels
leads to the inward flow of several cations such as potassium, sodium and calcium; but,
the major ion channel associated with nAChRs is the calcium ion channel. Flow of
calcium and other cations into the cell non-selectively through the open nAChRs causes
the electrical charge inside the plasma membrane to become positive, a process known as
depolarization. In turn, this depolarization of these cells stimulates voltage-gated calcium
channels leading to additional influx of calcium which leads to several cellular changes
including neurotransmitter synthesis and release [31,32].
For decades, the nAChRs were generally thought to be restricted to the nervous
system and at

neuro-muscular junctions. However, recent studies have found these

receptors and their physiological agonist acetylcholine to be expressed in mammalian
cells including cancer cells of the pancreas, lung, colon and breast [23,26,33]. These
receptors act as regulators of growth of normal and cancer cells by modulating a complex
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network involving both stimulatory and inhibitory neurotransmitters [23,26]. Binding of
nAChRs to their agonists results in several cellular changes induced by depolarization of
the cells which results in regulation of stimulatory and inhibitory neurotransmitters
synthesis and release which ultimately act to activate several pathways including cAMPsignaling pathways which ultimately results in stimulation of proliferation, migration and
angiogenesis and inhibition of apoptosis (Fig. 1) [23,26]. Several studies on different
types of nAChRs have found α3, 5 and 7-nAChRs to be stimulatory nAChRs that
stimulate the synthesis of the stimulatory neurotransmitters adrenaline and noradrenaline
which ultimately stimulate cellular growth and division. However, studies on α4β2nAChR have found it to be an inhibitory receptor involved in the synthesis and release of
the inhibitory neurotransmitter GABA thereby inhibiting cancer progression [23,26].
For years it was generally believed that activation of nAChRs requires the release of
acetylcholine from the nervous system. However, recent studies have shown that
acetylcholine and its synthesizing enzyme, choline acetyltransferase are also expressed in
mammalian cells including cancer cells such as those of the pancreas, lung, colon and
breast [26,33]. Moreover, recent research on nAChRs have found other agonists to
activate α3, 4, 5 and 7-nAChRs including ethanol, nicotine, NNK and NNN
[23,26,33,34].
Interestingly, while chronic exposure of most types of cellular receptors to their
agonists results in their down-regulation, chronic and acute exposure of nAChRs to their
agonists results in their up-regulation [23,26,32,35]. Moreover, exposure of these
receptors to nicotine which has a binding affinity to nAChRs that is ten times higher than
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acetylcholine results in the up-regulation of these receptors as well [23,26,36].
Interestingly however, research has found nicotine, NNK and acetylcholine to bind with
higher affinity to the heteromeric nAChRs, such as the α4β2-nAChR, than to the
homomeric nAChRs such as α3, 5 and 7-nAChRs [26,37,38]. This higher affinity of
these agents to the heteromeric nAChRs, particularly α4β2-nAChR, results in its longterm inactivation or desensitization [26,35]. However, the sensitivity of the homomeric
receptors α3, 5 and 7-nAChRs remains unaffected and chronic exposure of these
receptors to their agonists results in their hyper-activation [23,26,35]. Therefore, these
findings suggest that exposure of nAChRs to nicotine, NNK or even acetylcholine
provides a suitable environment for cancer cell growth due to up-regulation of the
stimulatory α3, 5 and 7-nAChRs and desensitization of the inhibitory α4β2-nAChR
[26,38-40].

Beta-adrenergic receptors
G protein-coupled receptors (GPCRs) are one of the largest families of cell membrane
receptors consisting of an extracellular ligand binding domain, seven transmembrane
domains and heteromeric G-protein subunits [41]. The heteromeric subunits are α, β and
γ subunits. Binding of a GPCR to its agonist results in the transformation of GDP to GTP,
which results in the activation of the receptor and dissociation of the G protein into GαGTP and Gβγ subunits. These active subunits in turn can activate ion channels, other
receptors and enzymes leading to several cellular reactions induced by the agonist [4244]. Interestingly, studies have found numerous types of Gα subunits that serve different
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functions in the cell. The Gαs subunit serves to activate adenylyl cyclase while on the
other hand, the Gαi inhibits adenylyl cyclase and the Gαq activate phospholipase C.
Therefore, depending of the type of Gα present in the GPCR, ligand binding can induce
different cellular reactions within the cell [41,45,46]. Once the ligand leaves the receptor,
the GTP is converted to GDP and the subunits of G-protein re-associate with each other
to form an inactive G-protein (GDP) bound state [42-44].
Beta-adrenergic receptors (β-ARs) are a family of G protein-coupled membrane
receptors expressed in most mammalian cells [47-49]. Studies have found three types of
β-ARs expressed in mammalian cells including β1, 2 and 3 adrenergic receptors. Beta 1
and 2 are expressed in most mammalian cells with beta 3 being limited to adipose tissues
[47-49]. Binding of these receptors to their agonists initiate several signaling cascades via
the Gαs subunit including the arachidonic acid (AA) pathway, Src/STAT pathway and the
adenylyl cyclase / cAMP / PKA / CREB pathway which also transactivates the epidermal
growth factor receptor (EGFR) cascade (Fig. 1) [47,50-54].
Intensive studies on β-ARs mechanism of action have found the stimulatory
catecholamine stress neurotransmitters, adrenaline and noradrenaline, to be the
physiological agonists of these receptors with adrenaline preferentially binding to beta 2
and noradrenaline to beta 1 [23,47,53,54]. These neurotransmitters are produced and
secreted from the adrenal medulla. Moreover, recent research has found these
neurotransmitters to be also regulated by nAChRs [26,53]. Thus, exposure of cells to
nicotine, acetylcholine or NNK leads to up-regulation of α3, 5 and 7-nAChRs which in
turn stimulates catecholamine synthesis. These catecholamines in turn activate the β-ARs
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initiating the pathways listed above [26,53,55]. While nicotine and acetylcholine can
indirectly activate the β-ARs via up-regulating of nAChRss, studies have found that NNK
can directly activate β-ARs via acting as an agonist to these receptors thus providing an
additional up-regulation of the signaling cascade [49,53].
With the significant role β-ARs serve in regulation of cancer and normal cell growth,
research have focused on blocking these receptors as a potential therapeutic option
against cancer growth. Studies have shown that growth of both human pancreatic duct
adenocarcinoma cells and pancreatic duct epithelial cells to be stimulated by β-ARs
agonists which ultimately result in the stimulation of proliferation, migration and
angiogenesis and inhibition of apoptosis in cAMP dependent manner. Interestingly,
studies by our laboratory have shown that the use of beta-blockers which have been
safely used as cardio-vascular therapeutics such as propranolol can inhibit these growth
stimulating pathways by blocking the activity of β-ARs thereby inhibiting adenylyl
cyclase activation and the subsequent cAMP synthesis [23,53,56,57]. These results
therefore suggest beta blockers as potential therapeutic options for the treatment and
prevention of cancer.

GABA as a potential therapeutic agent
Gamma-amino butyric acid, also known as GABA, is a non-essential amino acid that
helps maintain a proper balance between body and mind. It is the major inhibitory
neurotransmitter in the central nervous system that helps losing excess body fats and has
anti-aging properties [40,49,58,59]. Moreover, GABA is an FDA approved supplement
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found in many fruits and vegetables including almonds, nuts, oats, brown rice, berries,
tomatoes and grapes that is widely used to ease anxiety and promote sleep. In addition,
several studies have found GABA to exert anti-tumor activity preventing proliferation
and migration of cancer cells in the pancreas and lungs [49].
For decades, it was widely believed that GABA production was restricted to the
brain, recent studies have found this neurotransmitter and its receptors to be expressed in
several peripheral tissues and organs such as the pancreas and lungs [58]. In the pancreas,
GABA is synthesized in β-cells from glutamate in a reaction catalyzed by both isoforms
of glutamic acid decarboxylase (GAD), GAD65 and GAD67 in the presence of pyridoxal
as a cofactor [40,49].
In the pancreas and lungs, studies by our laboratory have found GABA production to
be regulated by α4β2-nAChR. Activation of this receptor results in an increase GABA
synthesis and secretion by both PDAC and pancreatic duct epithelial cells [40,49].
However, interestingly, exposure of this receptor to nicotine, NNK or ethanol induces
desensitization of the receptor until removal of the agent. This desensitization in turn
results in a reduction of GABA levels which provides an environment suitable for cancer
growth [23,40,49].
Studies have found GABA to be associated with 3 different types of receptors: the
ionotropic receptors GABAA and GABAC, and the G protein-coupled receptor GABAB
which exists as two isoforms termed GABABR1 and GABABR2 [49,60]. Both of the
GABAB receptors are G protein-coupled receptors coupled to the adenylyl cyclase
inhibiting G-protein subunit, Gαi. Studies on these receptors have found the GABAA and
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GABAC ionotropic receptors to mediate excitatory functions upon binding to GABA
while the GABAB receptors mediate GABA’s inhibitory functions via the Gαi subunit.
The Gαi subunit of the GABAB receptors act as powerful control for the cAMP-dependent
signaling pathways that drive proliferation, migration and angiogenesis of PDAC and
lung adenocarcinomas [49]. These GABAB receptors act as a physiological brake to
counteract the entire cAMP dependent stimulatory signaling activated by β-ARs (Fig. 1).
Binding of GABA or baclophen to the GABAB receptor, resulted in the inhibition of
adenylyl cyclase via its Gαi subunit. This in turn reduced intracellular cAMP levels and
phosphorylation of important signaling proteins downstream the β-ARs that are involved
in cell proliferation, migration and angiogenesis such as ERK, Src, CREB and Akt
[40,49,61].
While several studies have shown GABA to be a promising agent for the prevention
and therapy of PDAC via GABAB signaling, other studies have found GABA to have
stimulatory effects on these PDAC cell lines. These studies have shown that several
PDAC cell lines overexpress the π subunit of GABAA receptor, and only in these cell
lines that overexpress this subunit that GABA stimulate PDAC [62]. Binding of GABA
to the GABAA receptor in cells that overexpress the π subunit results in the activation of
calcium ion channel which depolarizes the cells. This depolarization in turn results in the
activation of voltage gated calcium channels further increasing calcium levels. Calcium
in turn binds to calmodulin which in turn activate several stimulatory pathways including
the mitogen activated protein kinase (MAPK) pathway [62].
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Despite these discrepancies in the effects of GABA in cancer growth, studies in
support of GABA as a therapeutic agent are far more frequent than those indicating
otherwise. In addition, studies by proton magnetic resonance of the brain have also
shown that smoking significantly reduced GABA levels which is in accord with our
findings in PDAC cells [62,63]. Although it has shown significant anti-tumor activity in
vitro and in vivo in PDAC and lung cancer, GABA anti-tumor effects have not been
tested clinically yet [40,49]. Thus, more research is needed to study the potential
therapeutic ability of this agent to help in the treatment and prevention of the fourth
leading cause of cancer deaths, pancreatic cancer [8,10].
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Appendix

Figure 1.Schematic diagram showing growth regulation of PDAC cells and normal
pancreatic duct epithelial cells via nicotinic acetylcholine receptors (nAChRs).
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CHAPTER III:
Pancreatic Cancer Cells and Normal Pancreatic Duct Epithelial Cells Express an
Autocrine Catecholamine Loop That is Activated by Nicotinic Acetylcholine
Receptors 3, 5 and 7
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“Molecular Cancer Research” on February 2012.

Mohammed H. Al-Wadei, Hussein A. N. Al-Wadei and Hildegard M. Schuller.
Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine
catecholamine loop that is activated by nicotinic acetylcholine receptors α3, α5, and α7.
Molecular Cancer Research. 2012 Feb; 10(2):239-49.

Corresponding Author:
Hildegard M Schuller, DVM, Ph.D.
Experimental Oncology Laboratory
Department of Biomedical & Diagnostic Sciences
College of Veterinary Medicine
University of Tennessee
2407 River Drive
Knoxville, TN 37996-4543
Phone: 865-974-8217
Fax: 865-974-5616
E-mail: hmsch@utk.edu

The use of “we” in this chapter refers to the contributions of the co-authors and I in the
project. My contributions in this paper include (1) running all experiments relevant to the
paper, (2) analysis and interpretation of the data, (3) statistical analysis of all data, (4)
photographic and graphic documentation of results, (5) manuscript writing. Co-authors
contributions to this paper include experimental design and writing editorial assistance by
Dr. Schuller and technical assistance by Dr. Hussein Al-Wadei.

30

Abstract
Pancreatic cancer is the fourth leading cause of cancer deaths in developed
countries. Smoking is an established risk factor for this malignancy but the underlying
mechanisms are poorly understood. Previous reports have provided evidence that
nicotinic acetylcholine receptors (nAChRs) and beta-adrenergic receptors (β-ARs)
stimulate the growth and migration of pancreatic cancer cells. But a potential cooperation
of these two receptor families in the regulation of pancreatic cancer has not been studied
to date. Using two pancreatic cancer cell lines and immortalized pancreatic duct epithelia
in vitro, our current data show, that all three cell lines synthesized and released the
catecholamine neurotransmitters noradrenaline and adrenaline upon exposure to nicotine
and that this activity was regulated by 3, 5, and 7-nAChRs. In accord with the
established function of these catecholamines as β-AR agonists, nicotine-induced cell
proliferation was blocked by the β-AR antagonist propranolol. Nicotine-induced
proliferation was also abolished by the α7-nAChR antagonist α-bungarotoxin while
catecholamine production in response to nicotine was blocked by gene knockdown of the
3, 5, and 7-nAChRs. The nicotinic agonists acetylcholine, nicotine, and its nitrosated
carcinogenic derivative NNK induced the phosphorylation of CREB, ERK, Src and AKT
and these responses were inhibited by propranolol. Our findings identify this hitherto
unknown autocrine catecholamine loop as an important regulatory cascade in pancreatic
cancer that may prove a promising new target for cancer intervention.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths with a morality rate
near 100 % within two years of diagnosis [1]. The major impediment to effective clinical
outcomes for this malignancy is its delayed diagnosis and resistance to existing cancer
therapeutics [2,3]. Novel strategies for more successful prevention and therapy of
pancreatic cancer are therefore urgently needed.
Pancreatic ductal adenocarcinoma (PDAC) accounts for the majority of pancreatic
cancer cases and is thought to arise from pancreatic duct epithelia [3]. Smoking is a
documented risk factor for pancreatic cancer [4], with smokers demonstrating a twofold
increase in the risk of developing PDAC [5]. Tobacco smoke is composed of over 4000
chemicals,

including

the

nicotine-derived

carcinogenic

nitrosamine

4-

(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [6]. It has been shown that NNK
causes PDAC in rats [7] and hamsters [8]. While nicotine acts as the primary
psychoactive component responsible for smoke addiction, it is thought to be noncarcinogenic. However, several laboratories have reported that nicotine activates
numerous cellular signaling pathways downstream of nicotinic acetylcholine receptors
(nAChRs), resulting in the stimulation of cell proliferation, angiogenesis, and metastasis
of several cancers, including PDAC [9-12].
Nicotinic acetylcholine receptors constitute a heterogeneous family of ion
channels that were initially thought to be restricted to the central and peripheral nervous
system. However, recent studies have identified the expression of this receptor family in
numerous non-neuronal cells, including the pancreas [13]. In the nervous system and
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adrenal glands, nAChRs regulate the synthesis of the catecholamine neurotransmitters
noradrenaline and adrenaline and their release into the extracellular environment and
systemic circulation [14,15]. Both catecholamines are agonists for β-adrenergic receptors
(β-ARs). Binding of adrenaline or noradrenaline to these receptors activates the
stimulatory G protein (Gαs) which in turn activates adenylyl cyclase, the single rate
limiting step for the formation of intracellular cAMP [16,17]. Moreover, studies by our
laboratory have shown that PDAC cells express β-ARs with β2-ARs predominating, and
that cAMP signaling downstream of these receptors stimulates the proliferation and
migration of these cells [18-20].
In the current experiments, we have tested the hypothesis that analogous to their
function in the CNS, nAChRs regulate the synthesis and release of noradrenaline and
adrenaline in PDAC cells and pancreatic duct epithelial cells and that this autocrine
catecholamine loop activates multiple cellular pathways that are overexpressed in
pancreatic cancer.

Materials and Methods
Chemicals, primers and antibodies
Lipofectamine 2000 Reagent, stealth-183 for the CHRNA7 gene, stealth-1079 for
the CHRNA3 gene, stealth-873 for the CHRNA5 gene, stealth-1973 for the CHRNA4
gene, stealth RNAi Negative Control Low GC Duplex, and Opti-MEM I reduced serum
medium 1X were all purchased from Invitrogen Corporation (Carlsbad, CA, USA). The
primer used to interfere with the α7 subunit mRNA was sense, GGA AGC UUU ACA
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AGG AGC UGG UCA A and antisense, UUG ACC AGC UCC UUG UAA AGC UUC
C. The primer used to interfere with the α3 subunit mRNA was sense, GCU CUU CCA
UGA ACC UCA AGG ACU A and antisense, UAG UCC UUG AGG UUC AUG GAA
GAG C. The primer used to interfere with the α5 subunit mRNA was sense, GGG AGC
AAA GGA AAC AGA ACC GAC A and antisense, UGU CGG UUC UGU UUC CUU
UGC UCC C. The primer used to interfere with the α4 subunit mRNA was sense, GAC
CGC AUC UUC CUC UGG AUG UUC A and antisense, UGA ACA UCC AGA GGA
AGA UGC GGU C.
The TE Buffer 1X was purchased from Promega Corporation (Madison, WI,
USA). The 2-Cat Elisa Kits were purchased from Rocky Mountain Diagnostics
Incorporation (Colorado Springs, CO, USA). ELISA kits for Akt [pS473], ERK1/2
[pTpY185/187], and CREB [pS133] were purchased from Invitrogen Corporation
(Carlsbad, CA, USA). The c-Src Kinase assay was purchased from MBL International
(Woburn, MA, USA).
The antibodies Akt (60 kDa), p-Akt (60 kDa), Src (60 kDa), p-Src (60 kDa), ERK
½ (44/42 kDa), p-ERK ½ (44/42 kDa), p-CREB (43 kDa), anti-rabbit and anti-mouse
were all purchased from Cell Signaling (Danvers, MA, USA). The primary antibodies
anti-CREB (43 kDa) and anti-nicotinic acetylcholine receptor alpha4 (55 kDa) were
purchased from Millipore (Billerica, MA, USA). The nicotinic acetylcholine receptor
subunits α7 (56 kDa), α3 (57 kDa), α5 (53 kDa), and β-actin (42 kDa) antibodies were
purchased from Abcam (Cambridge, MA, USA). Nicotine and propranolol were both
purchased from Sigma-Aldrich (St. Louis, MO, USA). The site-selective α7-nAChR
34

antagonist, α-bungarotoxin, was purchased from Calbiochem (Gibbstown, NJ, USA). The
lysis buffer used to extract proteins along with Pierce ECL western blotting substrate
were purchased from Thermo Scientific (Rockford, IL, USA).

Cell culture
The human pancreatic ductal adenocarcinoma cell lines Panc-1 and BxPC-3 were
purchased from the American Type Culture Collection (Manassas, VA, USA). The
immortalized human pancreatic duct epithelial cell line, HPDE6-C7, was clonally
established after transduction of the HPV16-E6E7 genes into primary cultures of
pancreatic duct epithelial cells and was a kind gift from Dr. Tsao (Division of Cellular
and Molecular Biology, Department of Pathology, Ontario Cancer Institute/Princess
Margaret Hospital, University of Toronto, Toronto, ON, Canada). All cell lines have been
authenticated at the beginning of the current study by RADIL (Research Animal
Diagnostic Laboratory, Columbia, MO, USA) by species-specific PCR evaluation.
The Panc-1 cell line was maintained in DMEM medium supplemented with 10 %
Fetal Bovine Serum (FBS). BxPC-3 cells were maintained in RPMI 1640 medium
supplemented with 10 % FBS. HPDE6-C7 cells were maintained in Keratinocyte Serum
Free Medium (KSFM) supplemented with 25 mg / 500 ml Bovine Pituitary Extract (BPE)
and 2.5 µg / 500 ml Epidermal Growth Factor (EGF) (GIBCO Invitrogen Corporation,
Grand Island, NY, USA). All cell lines were grown without antibiotics in an atmosphere
of 5 % CO2, 99 % relative humidity, and 37 o C.
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Analysis of intracellular and secreted adrenaline and noradrenaline
All three cell lines were maintained in their respective complete medium until
reaching 65 % confluence, at which time they were switched to basal medium for 24
hours starvation. Cells were then switched into fresh basal media and were divided into
two groups. The first groups of cells were either untreated or treated with 1 µM nicotine
for 1, 5, 15, or 30 minutes. The second groups of cells were either untreated or treated
with 10 pM, 500 pM, 1 nM, 500 nM, 1 µM, or 10 µM nicotine for 30 minutes. The
culture media, containing secreted catecholamines were then collected in 15 ml test tubes.
The cells which contained synthesized intracellular catecholamines were lysed and
harvested into 1.5 ml eppendorf tubes after a one time wash with warm 1X PBS.
Quantitative analyses of intracellular and secreted adrenaline and noradrenaline of five
samples per treatment group were conducted using 2-Cat ELISA kits following the
vendor’s recommendations. Absorbance of samples was read using an uQuant Bio-Tek
Instrument ELISA reader at 450 nm primary wavelength with a 630 nm reference
wavelength.

Gene knockdown of the α3, 4, 5, and 7-nAChRs
Cells from all three cell lines were grown for 24 hours in their respective
complete media. At that time, cells were switched to Opti-MEM I media and were
divided into several groups. Groups 1 and 2 from each cell line were left untreated in
Opti-MEM I media for 24 hours. Group 3 was transfected for 24 hours with stealth RNAi
Negative Control Low GC Duplex. Groups 4 and 5 were transfected with either stealth36

183, 1079, 873, or 1973 for the CHRNA7, 3, 5, and 4 genes respectively for 24 hours in
Opti-MEM I media. Once the 24 hours transfection was complete, all cells were switched
into their respective basal media. Groups 1, 3, and 4 were left untreated for 30 minutes in
basal media whereas groups 2 and 5 were treated with 1 µM nicotine for 30 minutes in
basal media. All transfections were done using Lipofectamine 2000 reagent following the
instructions of the manufacturer. Cell lysates were then harvested and collected in 1.5 ml
eppendorf tubes after one time wash with warm 1X PBS for adrenaline and noradrenaline
analyses by immunoassays as described above. The transfection efficiency was
monitored by western blots using α3, 4, 5 and 7-nAChRs as primary antibodies and actin
as a loading control following the procedure outlined below. Following background
subtraction, mean densities of 2 rectangular areas of standard size per band from three
independent westerns were determined and mean values and standard deviations (n = 6)
of protein expression were calculated.

Assessment of cell proliferation by MTT assay
Cells from the three cell lines were seeded in 6-well plates at a density of 50,000
cells per well in their respective phenol red free complete media. Cells were then left
untreated, or treated with 1 µM nicotine for 72 hours, 200 nM α-bungarotoxin for 72
hours, 1 µM propranolol for 72 hours, 200 nM α-bungarotoxin for 10 minutes followed
by 1 µM nicotine for 72 hours, or 1 µM propranolol for 10 minutes followed by 1 µM
nicotine

for

72

hours.

The

MTT

(3-[4,5-dimethylthiazol-2-yl]-2,5-

diphenyltetrazoliumbromide) colorimetric assay (Sigma-Aldrich St Louis, MO, USA)
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was used to assess cell proliferation following instructions by the vendor. The MTT
assay is based on the nicotinamide adenine dinucleotide-dependent enzymatic reduction
of the tetrazolium salt MTT to form formazan in metabolically active, viable cells.
Absorbance of samples was read using an uQuant Bio-Tek Instrument ELISA reader at
570 nm primary and 650 nm reference wavelengths.

Quantitative assessment of phosphorylation of signaling proteins by ELISA assays
Cells from the three cell lines were left to grow in their respective complete media
until reaching 65 % confluence. Cells were then left untreated, or treated with 1 µM
nicotine for 72 hours, 1 µM propranolol for 72 hours, or 1 µM propranolol for 10 minutes
followed by 1 µM nicotine for 72 hours in complete media. The cells were then lysed and
harvested into 1.5 ml eppendorf tubes after a one time wash with warm 1X PBS.
Quantitative analyses of Akt, CREB, Src, and ERK1/2 phosphorylation of five samples
per treatment group were conducted using Akt, CREB, c-Src, and ERK1/2 ELISA kits
respectively following the vendors’ recommendations. Absorbance of samples was read
using an uQuant Bio-Tek Instrument ELISA reader at 450 nm primary wavelength with a
630 nm reference wavelength.

Western blot analysis
Cells from HPDE6-C7, BxPC-3, and Panc-1 were grown in their respective
complete medium until reaching 65 % confluence. Cells were then switched to their
respective basal media without any supplements or antibiotics for 24 hours starvation.
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The cells were then switched to fresh basal media and were divided into three groups.
Group 1 was either untreated, or treated with 1 µM nicotine for 10, 15, 30 or 60 minutes.
Group 2 was either untreated, or treated with 1 nM NNK for 10, 15, 30 or 60 minutes.
Group 3 was either untreated, or treated with 10 µM acetylcholine for 10, 15, 30 or 60
minutes. Protein samples were prepared using lysis buffer (50-mmol / L Tris-HCl, 1 %
NP-40, 150-mmol / L NaCl, 1-mmol / L phenylmethysulfonylfluoride, 1-mmol / L
Na3VO4, 1-mmol / L NaF, and 1 µg / mL of aprotinin, leupeptin, and pepstatin). After
heat denaturation, protein samples were electrophoresed using 12 % SDS gels
(Invitrogen) and blotted onto membranes. The membranes were blocked (5 % nonfat dry
milk solution) for one hour at room temperature. Membranes were then incubated
overnight at 4 o C with the following primary antibodies: Akt, p-Akt, Src, p-Src, CREB,
p-CREB, ERK ½, and p-ERK 1/2. The membranes were then washed (0.5 % Tween 20 /
TBS) and incubated with their respective fluorescent secondary antibodies for two hours.
Protein bands were then visualized with enhanced chemiluminescence reagent (Pierce
ECL Western Blotting Detection Substrate).

Statistical analysis of data
GraphPad Instat 3 software (GraphPad Instant biostatistics, San Diego, CA, USA)
was used to test significant differences between different treatment groups. Statistical
tests used included non-parametric One Way ANOVA and Tukey-Kramer multiple
comparison tests. In addition, ImageJ from NIH was used for mean density determination
of bands. Data of the immunoassays and MTT assays are expressed as mean and + / 39

standard deviation of five samples per treatment group. The EC50 values of the
concentration-response curves were determined by nonlinear regression analysis.
Densitometry data of western blots are expressed as mean values and standard deviations
of 2 density determinations per band from three independent westerns per antibody (n =
6).

Results
Effects of nicotine on catecholamine neurotransmitter levels
One important role of the α7-nAChR in the nervous system is the regulation of
the synthesis and release of neurotransmitters, including adrenaline and noradrenaline
[14,21]. While our laboratory has previously shown that β-ARs regulate the proliferation
and migration of pancreatic cancer cells in vitro [18-20], the function of nAChRs
expressed in these cells is poorly understood. We therefore tested the hypothesis that
pancreatic ductal adenocarcinoma cells and normal pancreatic duct epithelial cells,
synthesize and release their own catecholamine neurotransmitters and that this activity is
regulated by nAChRs. In support of this hypothesis, our immunoassays detected
noradrenaline and adrenaline in cell lysates as well as culture media of both pancreatic
cancer cell lines and the immortalized pancreatic duct epithelial cells. The intracellular as
well as secreted levels of noradrenaline and adrenaline increased significantly (p <
0.0001) in a time-dependent manner when the cells were exposed to nicotine (1 µM) for
1 to 30 minutes (Figure 1). The immortalized duct epithelial cell line HPDE6-C7 was less
responsive to nicotine than the cancer cells (p < 0.0001 at the 30 minute time point) as
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indicated by lower levels of intracellular and secreted catecholamines at all-time points
investigated (Figure 1). Exposure of the cells for 30 minutes to nicotine at concentrations
from 10 pM through 10 µM additionally revealed concentration-dependent increases in
intracellular and secreted catecholamines in all three cell lines (Figure 2). In accord with
the differences in responsiveness observed in the time courses (Figure 1), the EC50 values
of nicotine for intracellular and secreted noradrenaline and adrenaline were in the
nanomolar range for the two cancer cell lines while they were in the 10-100 nanomolar
range for HPDE6-C7 cells (Figure 2).

Effects of nAChR knockdown on neurotransmitter levels and nAChR protein
To assess the potential regulatory role of the 3, 4, 5, and 7-nAChRs for
catecholamine synthesis in pancreatic cancer and pancreatic duct epithelial cells, the three
cell lines were transfected with stealth 3, 4, 5, or 7 RNAi constructs.
Immunoassays showed that transfections with the 3, 5, and 7 RNAi constructs
significantly inhibited (p < 0.0001) the stimulatory effect of nicotine on adrenaline and
noradrenaline synthesis in each of the three cell lines and reduced catecholamine
synthesis below base levels in control cells (Figure 3). These findings confirm regulatory
roles of the 3, 5, and 7-nAChRs for catecholamine production by these cells. By
contrast, gene knockdown of the α4-nAChR did not significantly reduce catecholamine
synthesis in either cell line (Figure 3). As no reduction in catecholamine synthesis was
observed in the cells transfected with the negative control RNAi, these findings indicate

41

that the cells also produce one or both of the physiological agonists for these nAChRs
(acetylcholine, choline) that continuously stimulated base level catecholamine synthesis.
Results of western blots showed significant increases (p < 0.0001) in the
expression of all investigated nAChR proteins in all three cell lines exposed for 30
minutes to 1 µM nicotine (Figure 4). Furthermore, transfection of these cells with stealth
RNAi for each of the investigated nAChR constructs significantly decreased (p < 0.0001)
their protein expression in cells with and without nicotine exposure (Figure 4). By
contrast, transfection of cells with stealth RNAi negative control low GC showed no
significant change in the protein expression of this receptor (Figure 4), confirming the
specificity of the observed gene knockdowns.

Activation of multiple signaling proteins by nAChR agonists and inhibition by the betablocker propranolol
Binding of an agonist to β-ARs activates adenylyl cyclase, leading to the
formation of cAMP and phosphorylation of the transcription factor CREB by activated
protein kinase A [17]. In addition, activated protein kinase A transactivates the EGFR
pathway in pancreatic cancer cells and pancreatic duct epithelia, leading to the
phosphorylation of the extracellular signal regulated kinases ERK1/2 [19]. We therefore
assessed the phosphorylation of CREB and ERK by western blots in our three cell lines
after exposures from 10 to 60 minutes to nicotine (1 µM), NNK (1 nM) or acetylcholine
(10 µM). We also monitored the phosphorylation of Src family tyrosine kinases and of
the serine / threonine protein kinase B, AKT, because both are frequently overexpressed
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in pancreatic cancer [22,23]. As Figure 5 shows, 1 µM nicotine induced the
phosphorylation of all four signaling proteins in both pancreatic cancer cell lines and
immortalized pancreatic duct epithelial cells. In accord with findings that the affinity of
NNK to the α7-nAChR is about 1000 times greater than that of nicotine [24], similar
responses of the four investigated signaling proteins were observed when the cells where
exposed to 1 nM NNK (Figure 5). The physiological nAChR agonist, acetylcholine,
binds to these receptors at a significantly lower affinity than nicotine [14]. We therefore
used acetylcholine at a 10 µM concentration when assessing its effects on the
phosphorylation status of the signaling proteins under investigation. As shown in Figure
5, at this concentration, acetylcholine had similar inducing effects on all four signaling
proteins as nicotine and NNK.

The quantitative assessment of nicotine-induced

activation of these signaling proteins and the inhibitory effects of propranolol were
achieved by immunoassays. As Figure 6 shows, the phosphorylation of ERK, CREB, Src
and AKT were each significantly (p < 0.001) induced by nicotine and these responses
were completely blocked by propranolol (p < 0.0001). Propranolol also significantly (p <
0.01) reduced base level phosphorylation of these signaling proteins in cells not exposed
to nicotine (Figure 6).

Regulation of cell proliferation by neurotransmitter receptors
MTT assays were conducted to evaluate cell proliferation of HPDE6-C7, BxPC-3,
and Panc-1 cells induced by nicotine (1 µM) in the presence and absence of the general
β-AR antagonist, propranolol (1 µM) or the site-selective α7-nAChR antagonist, α43

bungarotoxin (α-BTX, 200 nM). Cells from each of the three investigated cell lines
exposed to nicotine for 72 hours showed significant increases (p < 0.0001) in cell
proliferation. This response to nicotine was reduced below base levels (p < 0.0001) by
pre-exposure of cells to either α-BTX or propranolol (Figure 7a), indicating that the α7nAChR as well as β-ARs were involved in the observed nicotine-induced cell
proliferation. In addition, base level cell proliferation in the absence of nicotine was
significantly (p < 0.0001) reduced by α-BTX or propranolol (Figure 7a), suggesting
regulatory functions of both receptor types in non-exogenously stimulated cells.

Discussion
Our data show, for the first time, that pancreatic cancer cells and normal,
pancreatic duct epithelia, express an autocrine catecholamine loop that stimulates their
proliferation and is jointly regulated by the nAChRs 3, 5, 7 and by β-ARs. The
catecholamines noradrenaline and adrenaline, that were synthesized and released by two
investigated pancreatic cancer cell lines and a cell line of immortalized pancreatic duct
epithelia, are commonly known as stress neurotransmitters because they are synthesized
in the adrenal medulla and released into the systemic blood circulation in response to
psychological stress [15]. In addition, both of these neurotransmitters are synthesized and
released from nerves of the sympathicus [25], thus regulating vital functions in multiple
organs. Furthermore, noradrenaline and adrenaline have excitatory and anti-inflammatory
functions in the brain where they are synthesized and released by neurons [21]. It is well
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documented that nicotine increases catecholamine production at these neuroendocrine
sites, thus increasing the systemic levels of noradrenaline and adrenaline [26,27].
Accordingly, a previous study by our laboratory showed a significant nicotineinduced growth promotion of pancreatic cancer xenografts associated with increased
levels of noradrenaline, adrenaline and cAMP in blood and xenograft tissues as well as an
induction of p-CREB and p-ERK in xenograft tissues. These changes were interpreted as
indirect effects of such systemic neuroendocrine responses [28]. Our current in vitro
experiments are not influenced by this systemic neuroendocrine effect of nicotine and
unequivocally show that two pancreatic cancer cell lines as well as immortalized
pancreatic duct epithelia synthesized and released their own noradrenaline and adrenaline
in response to nicotine. The important role of the catecholamine neurotransmitters in the
observed nicotine-induced stimulation of cell proliferation was confirmed by abolishment
of this response by propranolol, an antagonist for β1- as well as β2-ARs. As assessed by
both, gene knockdown and pharmacological blockage with α-BTX, the α7-nAChR
regulated catecholamine production as well as cell proliferation in response to nicotine.
Interestingly, gene knockdown of the 3 and 5-nAChRs also significantly reduced
catecholamine production in all three cell lines, indicating cooperative function of these
two nAChRs with the 7-nAChR. By contrast, the 4-nAChR did not appear to
participate in the regulation of catecholamine production. These findings are in accord
with reports that the 3, 5, and 7-nAChRs cooperate in regulating the proliferation of
oral keratinocytes [29] whereas the 4-nAChR regulates the production of aminobutyric acid (GABA) in human small airway epithelial cells [30]. The 3, 5 and
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α7-nAChRs thus function as the upstream regulator of this novel autocrine regulatory
loop with β-ARs as the effectors of released noradrenaline and adrenaline (Figure 7b).
Our findings are in accord with recent observations that the α7-nAChR regulates
the synthesis and release of noradrenaline and adrenaline in small airway epithelial cells
[30] and colon cancer cells [31] and suggest this autocrine catecholamine loop as a novel
target for pancreatic cancer intervention. This interpretation is supported by our findings
that multiple phosphorylated signaling proteins that are frequently overexpressed in
pancreatic cancer were simultaneously induced in each of the investigated cell lines by
exposure to nicotine while the beta-blocker propranolol reversed these responses and
additionally reduced the phosphorylation of all investigated signaling protein levels
below base levels. These findings indicate that the observed phosphorylation of signaling
proteins were events downstream of beta-adrenergic receptors. Inhibitors of ERK, Src,
AKT and EGFR tyrosine kinases alone or in combination are currently being explored as
"targeted therapeutics' for pancreatic cancer, an approach that necessitates treatment of
the patient with multiple inhibitors [2,3]. Our current data suggest single agent therapy
with the beta-blocker propranolol as a novel alternative to this strategy.
While CREB, Src and AKT are traditionally considered downstream effectors of
the EGFR pathway in pancreatic cancer [3], in vitro studies with pancreatic cancer cell
lines and immortalized pancreatic duct epithelia have shown that ERK is also
phosphorylated simultaneously with CREB in response to beta-adrenergic agonists
following the PKA-dependent transactivation of the EGFR [19]. In addition, studies in
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ovarian cancer cells have identified the phosphorylation of Src in these cells as a cAMPdependent event in response to stress neurotransmitters [32].
The nitrosated carcinogenic nitrosamine NNK is a nAChR agonist with a
thousand-fold higher affinity to the α7-nAChR than nicotine [24,29]. In the current
experiments, exposures of the cells to NNK were therefore conducted at a 1 nM
concentration as opposed to 1 µM nicotine used in the accompanying experiments. In
turn, the documented lower affinity of acetylcholine to nAChRs than nicotine [14] was
the reason why we exposed our cell lines to 10 µM acetylcholine. As our western blots
show, the induction of the investigated signaling proteins was similar with all three
agents at the concentrations used. Exposure of the cells to 1 µM nicotine for 30 minutes
additionally upregulated the protein expression of nAChRs in the investigated three cell
lines. This response is in accord with the reported rapid increase of nAChR numbers in
response to nicotine or other agonists [33]. Similar effects of nicotine on the α7-nAChR
have been described in the brain and are thought to be caused by post-translational and
post-transcriptional mechanisms [34].
Smoking is a documented risk factor for the development of pancreatic cancer
[4]. However, this malignancy also develops in a significant number of nonsmokers.
While some of these cases are preceded by diabetes or pancreatitis, two additional known
risk factors for pancreatic cancer [4,35], our current findings suggest that psychological
stress may also contribute to the development and progression of this disease. While in
our experiments the production of catecholamines and resulting induction of multiple
signaling proteins that regulate cell proliferation, migration and apoptosis was induced by
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the exogenous addition of nAChR agonists to the cells, psychological stress triggers a
systemic increase in noradrenaline and adrenaline via activation of the pituitary/adrenal
system [15]. In analogy to reports that experimentally induced psychological stress
promotes the growth and metastasis of ovarian cancer via beta-adrenergic, cAMPdependent signaling [36], psychological stress may therefore also facilitate the
development of pancreatic cancer and promote the progression of this malignancy, thus
impairing therapeutic outcomes [37,38]. However, further studies are needed to address
this potential aspect of pancreatic cancer regulation.
In summary, our data suggest that the autocrine catecholamine loop expressed in
pancreatic cancer cells and in normal pancreatic duct epithelial cells that is jointly
governed by the α3, α5, and α7-nAChRs and β-ARs as an important regulatory network
that controls multiple signal transduction pathways known to be hyperactive in pancreatic
cancer. As shown in Figure 7, this entire cascade could theoretically be inhibited by betablockers, or by agents that inhibit the activation of adenylyl cyclase and associated
formation of cAMP. While the α7-nAChR has been suggested as a drug target for the
therapy of non-small cell lung cancer [39], the vital functions of this receptor in the
nervous system renders the use of α7-nAChR antagonists for cancer therapy problematic.
On the other hand, beta-blockers have been safely used for decades as cardiovascular
therapeutics and the beta-blocker propranolol prevented the development of NNKinduced pancreatic cancer in hamsters [38] . A recent report has also identified
significantly better clinical outcomes in breast cancer patients treated with beta-blockers
[40]. These findings are in accord with data that have shown stimulation of breast cancer
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cell proliferation by beta-adrenergic agonists in vitro [41,42] . In addition, it has been
shown that γ-amino butyric acid (GABA) inhibited the proliferation and migration of
pancreatic cancer cells in vitro via GABA-B receptor mediated inhibition of adenylyl
cyclase [20]. GABA also reversed the growth promoting effects of nicotine on pancreatic
cancer xenografts by reducing tumor cAMP levels [28]. GABA has been safely used as a
nutritional supplement for many years and selective GABA-B-receptor agonists are
widely used for the pharmacological management of spastic pain after spinal injuries and
spinal surgery. Further studies are now warranted to explore the potential usefulness of
these agents for the improvement of clinical outcomes in pancreatic cancer therapy.
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Appendix

Figure 1.Secreted (a) and intracellular (b) adrenaline levels; and secreted (c) and
intracellular (d) noradrenaline levels in HPDE6-C7, BxPC-3 and Panc-1 cells treated with
1 µM nicotine from 5 to 30 minutes. Representative data points are mean and + / - SD
from five samples per treatment group.
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Figure 2.Secreted (a) and intracellular (b) adrenaline levels; and secreted (c) and
intracellular (d) noradrenaline levels in HPDE6-C7, BxPC-3 and Panc-1 cells treated with
nicotine concentrations from 10 pM through 10 M for 30 minutes. Representative data
points are mean and + / - SD from five samples per treatment group.
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Figure 3.Assessment of the role of nAChR subunits in catecholamine production.
Receptor knockdown of alpha3, 5, and 7 significantly (p < 0.001) reduced nicotine
induced stimulation of intracellular (a) adrenaline and (b) noradrenaline. By contrast,
alpha4 receptor knockdown showed no significant effect on catecholamine production.
The columns in the graphs are mean and + / - SD from five samples per treatment group.
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Figure 4A-C.Western blots showing the effects of gene knockdown on protein
expression of alpha3, 4, 5, and 7-nicotinic acetylcholine receptors in HPDE6-C7 (a),
BxPC-3 (b) and Panc-1 (c) cells in the presence and absence of nicotine (1 M for 30
minutes). The house keeping protein β-actin was used as a control to ensure equal loading
of proteins.
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Figure 4D.Densitometric analysis of figures 4a-c. The columns represent means and + / SD of two mean density readings per band from three independent western blots (n = 6)
expressed as fold changes in expression of α3, 4, 5 and 7-nAChRs.
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Figure 5.Western blots assessing phosphorylation of Akt, Src, CREB, and ERK1/2 in
HPDE6-C7 (a), BxPC-3 (b) and Panc-1 (c) cells treated with 10 µM acetylcholine, 1 µM
nicotine and 1 nM NNK at different time exposures.
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Figure 6.ELISA assays showing phosphorylation levels of Src (a), ERK1/2 (b), Akt (c),
and CREB (d) for HPDE6-C7, BxPC-3 and Panc-1. Nicotine significantly (p < 0.001)
induced the phosphorylation of all signaling proteins investigated. Propranolol, a betablocker, significantly (p < 0.001) reduced base level and nicotine induced
phosphorylation of all four proteins. Representative data points are mean and + / - SD
from five samples per treatment group.
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Figure 7A.Cell proliferation of HPDE6-C7, BxPC-3 and Panc-1 cells assessed by MTT
assays showing inhibition of nicotine-induced cell proliferation by the site-selective α7nAChR antagonist, α-bungarotoxin (α-BTX), and by the beta-blocker propranolol.
Columns in the graph represents mean + / - SD of fiver samples per treatment group.
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Figure 7B.Schematic diagram of the proposed stimulation of pancreatic cancer cells by
the catecholamine loop that is jointly regulated by the 3, 5, and 7-nAChRs and -ARs.
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CHAPTER IV:
Effects of Chronic Nicotine on the Autocrine Regulation of Pancreatic Cancer Cells
and Pancreatic Duct Epithelial Cells by Stimulatory and Inhibitory
Neurotransmitters
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Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a mortality rate near 100 %.
Smoking is a documented risk factor. However, the mechanisms of smoking-associated
pancreatic carcinogenesis are poorly understood. We have shown that binding of nicotine
to nicotinic acetylcholine receptors (nAChRs) expressing subunits 7, 3, and 5 in
PDAC and pancreatic duct epithelial cells in vitro triggered the production of the
neurotransmitters noradrenaline and adrenaline by these cells. In turn, this autocrine
catecholamine loop significantly stimulated cell proliferation via cAMP-dependent
signaling downstream of beta-adrenergic receptors. However, the observed responses
only represent acute cellular reactions to single doses of nicotine whereas nicotine
exposure in smokers is chronic. Using the PDAC cell lines BxPC-3 and Panc-1 and
immortalized pancreatic duct epithelial cell line HPDE6-C7, our current experiments
reveal a significant sensitization of the nAChR-driven autocrine catecholamine regulatory
loop in cells pre-exposed for 7 days to nicotine. The resulting increase in catecholamine
production was associated with significant inductions in the phosphorylation of signaling
proteins ERK, CREB, Src and AKT, up-regulated protein expression of nAChR subunits
3, 4, 5, and 7 and increased responsiveness to nicotine in MTT and cell migration
assays. All three cell lines produced the inhibitory neurotransmitter -amino butyric acid
(GABA), an activity inhibited by gene knockdown of the 42nAChR and suppressed by
chronic nicotine via receptor desensitization. All of the observed adverse effects of
chronic nicotine were reversed by treatment of the cells with GABA, suggesting the

65

potential usefulness of this agent for the improvement of PDAC intervention strategies in
smokers.

Introduction
Pancreatic ductal adenocarcinoma (PDAC) comprises over 90 % of all pancreatic
cancers and has a mortality rate near 100 % within two years of diagnosis [1,2]. Smoking
is a documented risk factor [3-6] and smokers have a twofold risk to develop PDAC
[7,8]. However, the mechanisms of smoking-associated pancreatic carcinogenesis are
poorly understood. This lack of mechanistic insight may significantly contribute to the
poor clinical outcomes of currently available preventive and therapeutic strategies for
pancreatic cancer [9].
Among numerous carcinogenic and toxic substances contained in cigarette smoke,
nicotine has been widely studied because of its documented addictive properties [10,11].
Most biological effects of nicotine are mediated by nicotinic acetylcholine receptors
(nAChRs) which operate as pentameric ion channels enclosed by homomeric alpha
subunits or heteromeric alpha and beta-subunits [12]. Classic research on the function of
nAChRs has focused on the nervous system. However, discoveries that nAChRs regulate
the proliferation [13] and apoptosis [14] of lung cancer cells have triggered numerous
investigations on the regulatory role of this receptor family in a variety of cancers. It has
thus been shown that binding of nicotine to the homomeric 7nAChR stimulates the
proliferation, angiogenesis, neurogenesis and metastatic potential of the most common
human cancers (reviewed in [15]). The majority of these studies have interpreted the
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observed cancer stimulating effects of nicotine as direct signaling responses downstream
of the 7nAChR [15]. By contrast, we have recently shown that binding of nicotine to
nAChRs expressing subunits 7, 3 and 5 in PDAC and pancreatic duct epithelial cells
in vitro triggered the synthesis and release of the stress neurotransmitters noradrenaline
and adrenaline by these cells [16]. In turn, this autocrine catecholamine loop significantly
stimulated cell proliferation via cAMP-dependent signaling downstream of betaadrenergic receptors [16]. However, the observed responses only represent acute cellular
reactions to single doses of nicotine whereas nicotine exposure in smokers is chronic. Our
current experiments reveal significant sensitization of the nAChR-driven autocrine
catecholamine regulatory loop by chronic nicotine. In addition, our data show that PDAC
and pancreatic duct epithelial cells produce the inhibitory neurotransmitter aminobutyric acid (GABA), an activity regulated by the 42nAChR and desensitized by
chronic nicotine. Interestingly, all of these effects of chronic nicotine were reversed by
treatment of the cells with GABA.

Materials and Methods
Chemicals, primers and antibodies
Lipofectamine 2000 Reagent, stealth-1973 for the CHRNA4 gene, stealth RNAi
Negative Control Low GC Duplex, and Opti-MEM I reduced serum medium 1X were all
purchased from Invitrogen Corporation (Carlsbad, CA, USA). The primer used to
interfere with the α4 subunit mRNA was sense, GAC CGC AUC UUC CUC UGG AUG
UUC A and antisense, UGA ACA UCC AGA GGA AGA UGC GGU C.
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The TE Buffer 1X was purchased from Promega Corporation (Madison, WI,
USA). The 2-Cat and GABA-Research ELISA Kits were purchased from Rocky
Mountain Diagnostics Incorporation (Colorado Springs, CO, USA). ELISA kit for
Human Dopamine-Beta Hydroxylase was purchased from MyBioSource (San Diego, CA,
USA). ELISA kits for ERK1/2 [pTpY185/187] and CREB [pS133] were purchased from
Invitrogen Corporation (Carlsbad, CA, USA). The CytoSelect Cell Migration Assay was
purchased from Cell BioLabs, Inc. (San Diego, CA, USA).
The antibodies AKT (60 kDa), p-AKT (60 kDa), Src (60 kDa), p-Src (60 kDa),
anti-rabbit and anti-mouse were all purchased from Cell Signaling (Danvers, MA, USA).
The primary antibody anti-nicotinic acetylcholine receptor alpha4 (55 kDa) was
purchased from Millipore (Billerica, MA, USA). The nicotinic acetylcholine receptor
subunits α7 (56 kDa), α3 (57 kDa), α5 (53 kDa), GAD65 (65 kDa), GAD67 (67 kDa) and
β-actin (42 kDa) antibodies were purchased from Abcam (Cambridge, MA, USA).
Nicotine ((-)-Nicotine hydrogen tartrate salt, minimum 98 % TLC) and -aminobutyric
acid (GABA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The lysis
buffer used to extract proteins along with Pierce ECL western blotting substrate were
purchased from Thermo Scientific (Rockford, IL, USA).

Cell culture
The human pancreatic ductal adenocarcinoma cell lines Panc-1 and BxPC-3 were
purchased from the American Type Culture Collection (Manassas, VA, USA). The
immortalized human pancreatic duct epithelial cell line, HPDE6-C7, was clonally
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established after transduction of the HPV16-E6E7 genes into primary cultures of
pancreatic duct epithelial cells and was a kind gift from Dr. Tsao (Division of Cellular
and Molecular Biology, Department of Pathology, Ontario Cancer Institute/Princess
Margaret Hospital, University of Toronto, Toronto, ON, Canada). All cell lines have been
authenticated at the beginning of the current study by RADIL (Research Animal
Diagnostic Laboratory, Columbia, MO, USA) by species-specific PCR evaluation.
The Panc-1 cell line was maintained in DMEM medium supplemented with 10 %
Fetal Bovine Serum (FBS). BxPC-3 cells were maintained in RPMI 1640 medium
supplemented with 10 % FBS. HPDE6-C7 cells were maintained in Keratinocyte Serum
Free Medium (KSFM) supplemented with 25 mg / 500 ml Bovine Pituitary Extract (BPE)
and 2.5 µg / 500 ml Epidermal Growth Factor (EGF) (GIBCO Invitrogen Corporation,
Grand Island, NY, USA). All cell lines were grown without antibiotics in an atmosphere
of 5 % CO2, 99 % relative humidity, and 37 o C.

Analysis of intracellular and secreted GABA in response to acute nicotine treatments
All three cell lines were maintained in their respective complete medium until
reaching 65 % confluence, at which time they were switched to basal medium for 24
hours starvation. Cells were then switched into fresh basal media and were divided into
two groups. The first group of cells was either untreated or treated with 1 µM nicotine for
1, 5, 15, or 30 minutes. The second group of cells was either untreated or treated with 10
pM, 500 pM, 1 nM, 500 nM, 1 µM, or 10 µM nicotine for 30 minutes. The culture media,
containing secreted GABA were then collected in 15 ml test tubes. The cells which
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contained synthesized intracellular GABA were lysed and harvested into 1.5 ml
eppendorf tubes after a one time wash with warm 1X PBS. Quantitative analyses of
intracellular and secreted GABA of five samples per treatment group were conducted
using GABA-Research ELISA kit following the vendor’s recommendations. Absorbance
of samples was read using an uQuant Bio-Tek Instrument ELISA reader at 450 nm
primary wavelength with a 630 nm reference wavelength.

Analysis of total GABA, adrenaline and noradrenaline in response to chronic nicotine
Unpretreated cells from each cell line or cells pretreated for 7 days with nicotine
(1 M) were exposed to a range of nicotine concentrations (10 pM, 500 pM, 1 nM, 500
nM, 1 µM, or 10 µM) for 30 minutes prior to harvesting. For the 7 days treatment group,
media and treatment was replaced every 24 hours. The culture media, containing secreted
catecholamines and GABA were then collected in 15 ml test tubes. The cells which
contained synthesized intracellular catecholamines and GABA were lysed and harvested
into 1.5 ml eppendorf tubes after a one time wash with warm 1X PBS. Total (secreted
plus intracellular) catecholamines and GABA of five samples per treatment group was
analyzed using 2-Cat and GABA-Research ELISA kits respectively following the
vendor’s recommendations. Absorbance of samples was read using an uQuant Bio-Tek
Instrument ELISA reader at 450 nm primary wavelength with a 630 nm reference
wavelength.
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Gene knockdown of the α4nAChR
Cells from all three cell lines were grown for 24 hours in their respective
complete media. Cells were then switched to Opti-MEM I media and were divided into
several groups. Groups 1 and 2 from each cell line were left untreated in Opti-MEM I
media for 24 hours. Group 3 was transfected for 24 hours with stealth RNAi Negative
Control Low GC Duplex. Groups 4 and 5 were transfected with stealth-1973 for the
CHRNA4 gene for 24 hours in Opti-MEM I media. Once the 24 hours transfection was
complete, all cells were switched into their respective basal media. Groups 1, 3, and 4
were left untreated for 30 minutes in basal media whereas groups 2 and 5 were treated
with 1 µM nicotine for 30 minutes in basal media. All transfections were done using
Lipofectamine 2000 reagent following the instructions of the manufacturer. Cell lysates
were then harvested and collected in 1.5 ml eppendorf tubes after one time wash with
warm 1X PBS for GABA analysis by immunoassays as described above. The transfection
efficiency was assessed by western blots using α4-nAChR as the primary antibody and
actin as the loading control following the procedure which is outlined below. Following
background subtraction, mean densities of 2 rectangular areas of standard size per band
from three independent westerns were determined for the calculation of mean values and
standard deviations (n = 6) of protein expression.

Assessment of dopamine-beta hydroxylase levels
Cells from the three cell lines were divided into 4 groups. Group 1 was left
untreated. Group 2 was treated with 1 µM nicotine for 30 minutes. Group 3 was treated
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with 1 µM nicotine for 7 days. Group 4 was treated with 1 µM nicotine for 7 days
followed by 1 µM nicotine 30 minutes before harvesting. Media and treatments were
replaced every 24 hours for groups 3 and 4. The cells were then lysed and harvested into
1.5 ml eppendorf tubes after a one time wash with warm 1X PBS. Quantitative analyses
of dopamine-beta hydroxylase activity of five samples per treatment group were
conducted using human dopamine-beta hydroxylase ELISA kit following the vendor’s
recommendations. Absorbance of samples was read using an uQuant Bio-Tek Instrument
ELISA reader at 450 nm primary wavelength with a 630 nm reference wavelength.

Protein analyses by Western blotting and ELISA assays
The levels of phsophorylated signaling proteins ERK and CREB were assessed by
ELISA assays, using ERK1/2 [pTpY185/187] and CREB [pS133] ELISA kits from
Invitrogen. Absorbance of samples was read using an uQuant Bio-Tek Instrument ELISA
reader at 450 nm primary wavelength with a 630 nm reference wavelength.
Protein expression of nAChR subunits 3, 4, 5 and 7 as well as GAD65,
GAD67 and the phosporylated and unphosporylated forms of signaling proteins AKT and
Src was determined by Western blotting.
For both types of analysis, cells from HPDE6-C7, BxPC-3, and Panc-1 were
either untreated or treated with 1 µM nicotine, 30 µM GABA or GABA plus nicotine for
7 days in complete media. Media and treatments were changed every 24 hours for all
groups. Protein samples were prepared using lysis buffer (50-mmol / L Tris-HCl, 1 %
NP-40, 150-mmol / L NaCl, 1-mmol / L phenylmethysulfonylfluoride, 1-mmol / L
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Na3VO4, 1-mmol / L NaF, and 1 µg / mL of aprotinin, leupeptin, and pepstatin). After
heat denaturation, protein samples were electrophoresed using 12 % SDS gels
(Invitrogen) and blotted onto membranes. The membranes for Western blots were
blocked (5 % nonfat dry milk solution) for one hour at room temperature. Membranes of
group 1 were then incubated overnight at 4

o

C with the following primary antibodies:

nicotinic acetylcholine receptor subunit α3, 4, 5 and 7, GAD65, GAD67, p-AKT and pSrc determine expression or phosphorylation levels of these signaling proteins or
receptors. The primary antibodies Src, AKT and β-actin were used as a loading control
to ensure equal loading of proteins. All membranes were then washed (0.5 % Tween 20 /
TBS) and incubated with their respective fluorescent secondary antibodies for two hours.
Protein bands were then visualized with enhanced chemiluminescence reagent (Pierce
ECL Western Blotting Detection Substrate). Following background subtraction, mean
densities of 2 rectangular areas of standard size per band from three independent westerns
were determined and mean values and standard deviation (n = 6) of protein expression
were calculated.

Cell proliferation by MTT assay
Cells from the three cell lines were seeded in 6-well plates at a density of 20,000
cells per well in their respective complete media. Cells were then divided into 5 groups
(n=5). The first group of cells was left untreated for 7 days and harvested 24 hours later.
The second group was left untreated for 7 days, then treated with a single dose of 1 µM
nicotine that was removed 30 minutes later and harvested 24 hours later. The third group
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was treated with 30 µM GABA for 7 days and harvested 24 hours later. The fourth group
was treated with 1 µM nicotine for 7 days followed by a single dose of nicotine at the
EC50 concentration of nicotine established in the ELISA assays for adrenaline production
after chronic nicotine for each cell line (Figures 2d, e, and f: 1.184 nM for HPDE6-C7,
13.96 nM for BxPC-3 and 14.14 nM for Panc-1) that was removed 30 minutes later and
harvested 24 hours later. The fifth group was similar to the fourth one except that these
cells were additionally pre-treated with 30 µM GABA for 7 days. The MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide)

colorimetric

assay

(Sigma-

Aldrich St Louis, MO, USA) was used to assess cell proliferation following instructions
by the vendor. This assay is based on the cleavage of the tetrazolium salt MTT to
formazan in metabolically active cells. Absorbance of samples was read using an uQuant
Bio-Tek Instrument ELISA reader at a primary and reference wavelengths of 570 nm and
650 nm respectively.

Cell migration assay
Using 6-well plates that contain polycarbonate membrane filter inserts (8 µM
pore size) provided by a cell migration assay kit (Cell BioLabs, San Diego, CA, USA),
cells from each cell line were seeded onto the top chamber above the filter insert at a
density of 20,000 cells per well in their respective complete media. Cells were then
divided into identical treatment groups (n=5) as described for the MTT assays (above).
Migration ability of the cells was assessed following the instructions provided in the kit.
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Optical density of samples was read at 560 nm using an uQuant Bio-Tek Instrument
ELISA reader.

Statistical analysis of data
GraphPad Instat 3 software (GraphPad Instant biostatistics, San Diego, CA, USA)
was used for the transformation of data to fold increase and normalization and to test
significant differences among treatment groups. Statistical tests used included parametric
One Way ANOVA and Tukey-Kramer multiple comparison test when the data followed a
normal distribution. When data failed to pass the normality test of Kolmogorov and
Smirnov provide by the GraphPad software, they were instead analyzed by nonparametric Kruskal-Wallis ANOVA followed by the non-parametric Dunn’s multiple
comparison test. In addition, ImageJ from NIH was used for mean density determination
of bands from three independent Westen blots. Data of the immunoassays are expressed
as mean and + / - standard deviation of five samples per treatment group. Densitometry
data of western blots are expressed as mean values and standard deviations of 2 density
determinations per band from three independent westerns per antibody (n = 6). Nonlinear
regression analysis of sigmoidal dose-response curves for GABA, noradrenaline and
adrenaline was used to determine EC50 values of dose-response curves for nicotine in
unpretreated and 7-day pretreated cells.
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Results
Effects of acute and chronic nicotine on GABA levels
Studies by our laboratory have shown that treatment of PDAC cells with GABA
in vitro [17] and in mouse xenografts [18] inhibits tumor growth. Contrary to widely held
belief that the production and release of pancreatic GABA is restricted to the endocrine
cells of pancreatic islets [19], our data show that both PDAC and the pancreatic duct
epithelial cells synthesize and release GABA in vitro (Figures 1a-b and Figures 2a-c).
Exposure of the cells to single doses of nicotine (1 M) over time revealed a timedependent decrease (p < 0.0001) in synthesis and release of GABA (Figures 1a-b). Gene
knock-down of the 4nAChR subunit significantly (p < 0.001) reduced GABA levels in
untreated cells while additionally decreasing the nicotine-induced suppression of GABA
(Figure 1c). Moreover, gene knockdown of the 4-nAChR showed a significant (p <
0.0001) reduction in its protein expression and significantly reduced nicotine induced
expression of the receptor (Figure 1d). These findings identify nAChRs expressing the 4
subunit as important regulators of GABA production in the three investigated cell lines.
Acute exposure of cells for 30 minutes to single doses of nicotine at
concentrations from 10 pM through 10 µM revealed concentration-dependent decrease in
total (intracellular plus secreted) GABA in all three cell lines (Figures 2a-c). The
suppression of total GABA by identical concentrations of nicotine was enhanced even
further in cells pretreated for 7 days with nicotine (Figures 2a-c) and the EC50 values of
nicotine that caused these responses were significantly (p < 0.0001) lower after chronic
nicotine than in the un-pretreated cells.
76

Effects of chronic nicotine on production of noradrenaline and adrenaline
We have previously shown that exposure of the three investigated cell lines to a
single dose of nicotine causes synthesis and release of the catecholamine
neurotransmitters noradrenaline and adrenaline, both of which stimulated cell
proliferation [16]. In accord with these findings, our current results show a significant
and concentration dependent increase (p < 0.0001) in total adrenaline (Figures 2d-f) and
noradrenaline (Figures 3a-c) in unpretreated cells exposed to concentrations of nicotine
from 10 pM to 10 M for 30 minutes. The production of both catecholamines was
markedly enhanced (p < 0.0001) and EC50 values were significantly reduced when the
cells were pretreated for 7 days with nicotine and then exposed for 30 minutes to
identical concentrations of nicotine (Figures 2d-f and Figures 3a-c). In accord with these
findings, the levels of the enzyme dopamine-beta-hydroxylase, which catalyzes the
formation of noradrenaline from dopamine, were significantly (p < 0.0001) increased
after 30 minutes of exposure to 1 M nicotine in all three cell lines (Figure 3d). In turn,
chronic exposure to nicotine for 7 days further upregulated the expression of this enzyme
(Figure 3d).

Effects of chronic nicotine in the presence and absence of GABA treatment on protein
expression of nAChRs
We have previously shown that nAChRs with subunits α3, 5 and 7nAChRs jointly
regulated the production of noradrenaline and adrenaline in the three investigated cell
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lines [16] while our current data identified the 4nAChR as the regulator of GABA
production. We therefore assessed the effects of chronic nicotine in the presence and
absence of GABA on the protein expression of these receptors using western blots. As
shown in Figures 4a and b, chronic nicotine significantly induced (p < 0.0001) the protein
expression of all 4 receptors in each of the three cell lines. GABA treatment alone did not
significantly change the expression of these receptors as compared with the control
groups (Figure 4b). However, the protein induction of all 4 receptors in response to
chronic nicotine was significantly (p < 0.001) reduced by simultaneous chronic exposure
of each cell line to GABA (Figure 4b).

Effects of chronic nicotine in the presence and absence of GABA on phosporylated
signaling proteins
Binding of agonists to β-ARs activates adenylyl cyclase, leading to the formation
of cAMP and phosphorylation of the transcription factor CREB by activated protein
kinase A [20]. In addition, activated protein kinase A transactivates the EGFR pathway in
pancreatic cancer cells and pancreatic duct epithelia, leading to the phosphorylation of
the extracellular signal regulated kinases ERK1/2 [21] and activation of the Src and AKT
pathways [16]. We therefore assessed the phosphorylation of AKT and Src by semiquantitative western blotting in our three cell lines after exposures to nicotine, GABA or
the combination of both agents for 7 days. ELISA assays were used to monitor the
phosphorylation of CREB and ERK. As figures 5a and b show, chronic 1 µM nicotine
significantly (p < 0.0001) induced phosphorylation of AKT and Src signaling proteins in
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both pancreatic cancer cell lines and immortalized pancreatic duct epithelial cells.
Simultaneous chronic exposure of the cells to GABA significantly (p < 0.0001) reduced
the induction of both phosphorylated proteins by chronic nicotine while chronic GABA
treatment of unpretreated cells suppressed the activation of these proteins to near
background levels (Figures 5a-b). Analysis of p-ERK and p-CREB by ELISA assays
revealed a similar trend with significant (p < 0.0001) inductions by chronic nicotine and
significant (p < 0.001) reversal of these effects by treatment with GABA (Figure 6a).

Effects of chronic nicotine in the presence and absence of GABA on the GABA
synthesizing enzymes GAD65 and GAD67
The isozymes GAD65 and GAD67 catalyze the formation of GABA from
glutamate [22]. Having shown that our investigated cell lines produce GABA in vitro, we
therefore investigated the levels of GAD65 and GAD67 by Western blots in cells
exposed to 1 µM nicotine for 7 days in the presence and absence of simultaneous
treatment with GABA. Our data show a significant nicotine-induced reduction (p <
0.0001) in the expression of both isozymes as compared with the controls. These
responses were significantly (p < 0.0001) reversed by simultaneous chronic treatment
with GABA while GABA treatment alone significantly (p < 0.001) increased GAD levels
in unpretreated cells (Figures 5a, c).
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Effects of chronic nicotine in the presence and absence of GABA on cell proliferation and
migration
We have previously shown that blocking α7-nAChR by its selective antagonist,
alpha-bungarotoxin, or of β-adrenergic receptors by propranolol significantly reduced cell
proliferation induced by a single dose of nicotine in unpretreated PDAC cells [16]. In the
current study, we assessed cell proliferation as an indicator of tumor growth and cell
migration as an indicator of metastatic potential. Both assays revealed a significant (p <
0.0001) increase in cellular responsiveness to a single dose of nicotine in the cells
pretreated for 7 days with nicotine in comparison to unpretreated cells (Figures 6b, c).
When the pretreatment with nicotine was accompanied by 7 days of pretreatment with
GABA, the observed increased sensitivity to nicotine was significantly reduced (p <
0.0001; Figures 6b-c).

Discussion
Smoking is an important risk factor for pancreatic cancer [1]. However, the
mechanisms of smoking-associated pancreatic carcinogenesis are far from understood.
Recent studies by our laboratory have shown that the proliferation of the three currently
investigated cell lines is significantly stimulated by the activation of an autocrine
catecholamine loop regulated by α3, 5 and 7nAChRs upon acute exposure to single doses
of nicotine [16]. Single doses of nicotine thus activated multiple signaling proteins
commonly overexpressed in pancreatic cancer via noradrenaline/adrenaline-induced
cAMP-dependent signaling downstream of beta-adrenergic receptors [16]. Our current
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study extends these findings to show that all three cell lines additionally synthesize and
secrete GABA, a neurotransmitter previously identified by us as a potent tumor
suppressor for PDCA in vitro [17] and in xenograft models [18]. This novel finding
contrasts the widely held belief that endocrine beta cells in the pancreatic islets are the
sole source of pancreatic GABA that is transported to the exocrine pancreas via the
pancreatic blood circulation [22]. The observed significant reduction of GABA
production in untreated cells and inhibition of nicotine-induced GABA suppression by
gene knockdown of the 4nAChR additionally identifies this nAChR as the upstream
regulator of GABA in all three cell lines. Normal pancreatic duct epithelial cells as well
as PDAC cells thus express the complete machinery for the regulation of their own
growth stimulation and inhibition by neurotransmitters.
The observed chronic nicotine-induced increase in receptor protein of nAChRs
3, 5, and 7 in conjunction with significantly reduced EC50 values yielding
significantly higher levels of catecholamine production indicate sensitization of these
receptors by chronic nicotine. By contrast, the significantly reduced EC50 values for
nicotine-induced GABA production in conjunction with significant suppression of GAD
and GABA levels in cells chronically exposed to nicotine suggest that the observed
increase in protein of the GABA regulating 4nAChR was a reaction to desensitization
of the receptor. This interpretation gains strong support from the significant increases in
sensitivity to nicotine in 7 day nicotine pretreated cells observed in cell proliferation and
cell migration assays. Our findings are in accord with changes of these receptors in the
nicotine addicted brain [23] and imply a shift of neurotransmitter-mediated autocrine
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regulation of pancreatic duct epithelial cells and PDAC cells from a balanced state to
selective prevalence of cancer stimulating catecholamine neurotransmitters accompanied
by suppression of the inhibitory GABA system by chronic nicotine. This effect is further
exacerbated by the observed significant increase in dopamine-beta-hydroxylase levels by
chronic nicotine as the induction of this enzyme leads to increased synthesis of
noradrenaline.
The observed participation of three different nAChRs (α3, α5, α7) in the
regulation of catecholamine production is in accord with the reported redundance of these
cancer stimulating receptors in other epithelial cells [24]. In fact sequential investigations
have shown, that chronic exposure of oral keratinocytes to nicotine initially induce the
protein expression of nAChRs containing subunit complexes comprised of 3, 5, 2
and 4 followed by induction of the homomeric 7nAChR protein [25]. In turn, this
sequence in nAChR upregulation may be a reflection of the differences in the magnitude
of Ca2+ influx in response to agonist among nAChRs, with the a7nAChR demonstrating
the greatest permeability to Ca2+. The regulatory role of nAChRs expressing the 4
subunit for GABA synthesis and release observed in our current experiments is in accord
with similar findings in human small airway epithelial cells and lung adenocaricnomas
with phenotypic features of these cells [26]. However, contrary to the 7nAChR whose
stimulatory role on numerous cancers has been widely published [15], current knowledge
on the role of the 4nAChR in the regulation of cancer is rudimentary at best. The
desensitization of this receptors and associated suppression of GABA by chronic nicotine
in the brain is considered a major cause of nicotine addiction [23]. Our current data imply
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that analogous events in pancreatic duct epithelial and PDAC cells significantly increase
their propensity for cancerous growth and metastasis.
The signaling proteins ERK, Src and AKT are commonly overexpressed in PDAC
[27-29] and are current targets of pancreatic cancer therapy albeit with little success [9].
Our recently published investigations on the cellular responses of PDAC cells to a single
dose of nicotine have shown that all three of these signaling proteins as well as CREB are
phosphorylated when the nAChR triggered increase in noradenaline/adrenaline activates
beta-adrenergic receptor signaling [16]. Our current data show additional significant
increases over single dose acute nicotine treatments in the activated forms of these
proteins in cells chronically exposed to nicotine. In conjunction with the observed
changes in nAChRs, catecholamine and GABA production, chronic nicotine thus has
deleterious effects at several levels on the complex network that governs the growth
regulation of PDAC and pancreatic duct epithelial cells.
The significant reduction of all investigated effects of chronic nicotine in the
current experiments by simultaneous chronic treatment of our three cell lines with GABA
provides a mechanistic explanation for the reported reversal of nicotine-induced
progression of PDAC xenografts by GABA treatment [18]. We have previously
established that the nicotine-induced phosphorylation of CREB, ERK, Src and AKT are
cAMP-dependent events in the signaling pathway downstream of beta-adrenergic
receptors [21,30] and that GABA inhibits the formation of cAMP via the Gi-coupled
GABA-B receptor [17]. The strong reversal by GABA treatment of increased levels in
these phosphorylated signaling proteins as well as cellular responsiveness in proliferation
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and migration assays in response to chronic nicotine was therefore an expected outcome
of the current study. However, it is noteworthy that GABA also significantly reduced the
chronic nicotine-induced modulations in the expression and function of all investigated
nAChRs as well as the induction of dopamine-beta-hydroxylase and suppression of GAD.
These findings are in accord with observations in the nervous system that some of the
posttranscriptional mechanisms that cause the nicotine-induced upregulation of nAChR
protein are caused by increases in cAMP [31]. On the other hand, mechanisms involved
in the observed effects of GABA on nicotine-induced changes in dopamine-betahydroxylase and GAD expression need yet to be elucidated.
The beneficial effects of GABA on chronic nicotine-induced changes in the auto
regulation of PDCA cells and pancreatic duct epithelial cells of our current experiments
are in accord with previous reports that GABA inhibits the norepinephrine-induced
migration of cell lines from cancer of the colon [32] and mammary gland [33] and has
strong tumor suppressor function in lung adenocarcinoma in vitro [34] and in PDAC
xenografts [17].

However, in PDAC cell lines that overexpressed the pisubunit of

GABA-A receptors , GABA stimulated cell growth, an effect thought to involve reversal
of receptor function from hyperpolarizing to depolarizing, leading to an increase in
intracellular calcium levels [35].
Nicotine is generally classified as a non-carcinogenic agent because it does not
cause cancer in healthy experimental animals. However, it has been shown that
sensitization of lung nAChRs by pathologically increased CO2 levels that increase Ca2+
influx rendered nicotine a lung carcinogen in hamsters [36]. Our current data provide
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strong evidence for a key role of nicotine in the development and progression of
pancreatic cancer of individuals with modulated nAChR functions due to chronic nicotine
exposure. While blocking upstream regulatory receptors such as the α3, 4, 5 and
7nAChRs and β-adrenergic receptors may inhibit nicotine induced cell proliferation,
angiogenesis, and migration of pancreatic cells [16], the use of such agents for cancer
intervention is problematic due to the important functions of these receptors in the
regulation of the nervous system, cardiovascular functions and immune responses. In
addition, the presence of beta-adrenergic agonists and stimulators of cAMP in numerous
widely used over the counter drugs would effectively nullify any beneficial effects of
nAChR blockage. GABA, on the other hand, offers the promise to significantly improve
clinical outcomes of pancreatic cancers that do not overexpress the GABA-A receptor pi
subunit and may be suitable for the prevention of this malignancy in smokers.
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Appendix

Figure 1A-C.Secreted (a) and intracellular (b) GABA levels in HPDE6-C7, BxPC-3 and
Panc-1 cells treated with 1 µM nicotine from 1 to 30 minutes. (c) ELISA assays showing
intracellular GABA levels in cells in the presence and absence of gene knockdown of the
4-nAChR in the presence and absence of 1 μM nicotine for 30 minutes. Data points are
mean and + / - SD from five samples per treatment group.
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Figure 1D.Western blots showing the effects of gene knockdown on protein expression
of the 4-nAChR in the presence and absence of nicotine (1 M for 30 minutes). The
house keeping protein β-actin was used as a control to ensure equal loading of proteins.
The columns in the graph represent means and + / - SD of two mean density readings per
band from three independent western blots (n = 6) expressed as fold changes in
expression of α4-nAChR.
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Figure 2.Total (secreted plus intracellular) GABA levels (a-c) and total (secreted plus
intracellular) adrenaline levels (d-f) in HPDE6-C7, BxPC-3 and Panc-1 cells treated with
single doses of nicotine from 10 pM through 10 M for 30 minutes or pretreated with 1
M nicotine for 7 days and then exposed to identical concentrations of nicotine. Data
points are mean and + / - SD from five samples per treatment group.
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Figure 3.Total (secreted plus intracellular) noradrenaline levels (a-c) in HPDE6-C7,
BxPC-3 and Panc-1 cells treated with single doses of nicotine from 10 pM through 10
M for 30 minutes or pretreated with 1 M nicotine for 7 days and then exposed to
identical concentrations of nicotine. Levels of dopamine-beta hydroxylase

(d) in

HPDE6-C7, BxPC-3 and Panc-1 cells treated with 1 M nicotine for 30 minutes,
pretreated with 1 M nicotine for 7 days , or pretreated with 1 M nicotine for 7 days
followed by 30 minute nicotine treatment prior to harvesting. Data points are mean and +
/ - SD from five samples per treatment group.
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Figure 4.Western blots assessing protein expression of nAChR subunits 3, 4, 5 and
7 in HPDE6-C7, BxPC-3 and Panc-1 cells treated with 1 µM nicotine, 30 µM GABA or
GABA + nicotine for 7 days. The house keeping protein β-actin was used as a control to
ensure equal loading of proteins (a). The columns in graph (b) represent means and + / SD of two mean density readings per band from three independent western blots (n = 6)
expressed as fold changes in expression of α3, 4, 5 and 7-nAChRs.
94

Figure 5A-B.Western blots assessing phosphorylation of AKT, Src, GAD65 and GAD67
in cells treated with 1 µM nicotine, 30 µM GABA and GABA + nicotine for 7 days (a).
The columns in graph (b) represent means and + / - SD of two mean density readings per
band from three independent western blots (n = 6). The un-phosphorylated proteins AKT,
Src and β-actin were used as controls to ensure equal loading of proteins.
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Figure 5C.Densitometric analysis of GAD65 and GAD67 western bands presented in
figure 5a. The columns represent means and + / - SD of two mean density readings per
band from three independent western blots (n = 6) expressed as fold changes in protein
phosphorylation.
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Figure 6A.Phosphorylation of CREB and ERK assessed by ELISA assays in HPDE6-C7,
BxPC-3 and Panc-1 cells showing inhibition of nicotine-induced phosphorylation of these
signaling proteins by GABA. The columns represent means and + / - SD of 5 samples per
treatment group.
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Figure 6B-C.Cell proliferation (b) assessed by MTT assays and metastatic potential (c)
assessed by cell migration assays in HPDE6-C7, BxPC-3 and Panc-1 cells showing
inhibition of nicotine-induced cell proliferation and migration by GABA. The columns
represent means and + / - SD of 5 samples per treatment group.
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CHAPTER V:
Interaction of Chronic Ethanol with Nicotinic Receptor-Mediated Regulation of
Pancreatic Cancer Cells and Pancreatic Duct Epithelia
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Abstract
Pancreatic cancer has a high mortality rate and smoking and alcoholism are risk
factors. We have shown that nicotinic acetylcholine receptors (nAChRs) regulate
pancreatic ductal epithelia and pancreatic ductal adenocarcinoma (PDAC) cells in an
autocrine fashion by stimulating their production of noradrenaline and adrenaline while
suppressing γ-amino butyric acid (GABA). Our current study has investigated the effects
of chronic ethanol on the expression and regulatory function of these receptors and
explored potential cooperative effects of chronic ethanol with chronic nicotine. Using
MTT assays, cell migration assays, Western blotting and immunoassays in two PDAC
cell lines and in immortalized human pancreatic duct epithelial cells, our data show that
chronic ethanol increases cell proliferation and migration via increased catecholamine
synthesis and suppression of inhibitory GABA by modulating the protein expression and
responsiveness of nAChRs 3, 4, 5 and 7. GABA reversed all effects of ethanol
whereas chronic nicotine enhanced the responses to ethanol. Our findings suggest that
alcoholism and smoking cooperatively induce multiple nAChR-dependent cancer
stimulating signaling pathways while suppressing cancer inhibitory GABA. Our data
identify GABA as a promising agent for the prevention of PDAC in individuals at risk
due to chronic alcohol consumption and smoking.

Introduction
Pancreatic ductal adenocarcinoma (PDAC), which has phenotypic and functional
features of pancreatic duct epithelial cells, is one of the most aggressive neoplastic
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diseases with a mortality rate near 100 % within one year of diagnosis [1,2]. The poor
prognosis of PDAC is caused by its unresponsiveness to available therapeutics and its
propensity to grow asymptomatically until it has reached an advanced stage [3,4].
Smoking, chronic alcohol consumption and alcoholism-induced pancreatitis are
documented risk factors for PDAC [5-8]. Numerous publications have focused on the
mechanisms how nicotine, its nitrosated carcinogenic derivative NNK and other tobacco
related carcinogens stimulate pancreatic cancer development and progression [9]. We
have recently identified an important role of nicotinic acetylcholine receptors (nAChRs)
and neurotransmitters controlled by these receptors in the regulation of PDAC
proliferation and migration in vitro [10]. Binding of nicotine or its nitrosated
carcinogenic derivative 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to the
α3, 5 and 7-nAChRs resulted in the synthesis and release of adrenaline and
noradrenaline

[10], which are β-adrenergic receptor agonists that activate adenylyl

cyclase [11,12]. In turn, this reaction increased cAMP synthesis, leading to induction of
cell proliferation, migration and angiogenesis via cAMP-dependent signaling [10,13-15].
While the α4-nAChR was not involved in the regulation of noradrenaline and
adrenaline in these cells, it regulated the synthesis and release of the inhibitory
neurotransmitter GABA and chronic nicotine desensitized this receptor, thereby reducing
GABA production [10,14,16]. These findings identified the suppression of GABA as an
important event in facilitating PDAC development and progression and suggested that
nutritional supplementation with GABA may have anti-cancer activity on PDAC via the
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GABA-B receptor-mediated inhibition of adenylyl cyclase activation observed in vitro
[14].
In the current experiments, we have investigated the effects of chronic ethanol on
the protein expression and responsiveness of nAChRs 34, 5 and 7 in immortalized
pancreatic duct epithelial cells and two PDAC cell lines and analyzed the effects of these
changes on neurotransmitter production, cell proliferation, cell migration and activation
of key signaling proteins. Moreover, we have tested the potential inhibition of these
cellular responses by GABA and explored potential cooperative effects of chronic
ethanol and chronic nicotine on these nAChRs and their downstream effectors.

Materials and Methods
Chemicals, antibodies and assay kits
The

MTT

(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide)

colorimetric assay kit was purchased from Sigma-Aldrich (St Louis, MO, USA). The
CytoSelect Cell Migration Assay kit was purchased from Cell BioLabs, Inc. (San Diego,
CA, USA).
The 2-Cat and GABA Research ELISA Kits were purchased from Rocky
Mountain Diagnostics Incorporation (Colorado Springs, CO, USA). ELISA kits for Akt
[pS473], ERK1/2 [pTpY185/187], and CREB [pS133] were purchased from Invitrogen
Corporation (Carlsbad, CA, USA). The c-Src Kinase assay kit was purchased from MBL
International (Woburn, MA, USA). Both the cAMP and PKA activity ELISA assays were
purchased from Enzo Life Sciences (Farmingdale, NY, USA).
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The antibodies anti-rabbit and anti-mouse were purchased from Cell Signaling
(Danvers, MA, USA). The primary antibody anti-nicotinic acetylcholine receptor alpha4
(55 kDa) was purchased from Millipore (Billerica, MA, USA). The nicotinic
acetylcholine receptor subunits α7 (56 kDa), α3 (57 kDa) and α5 (53 kDa) antibodies as
well as GAD65 (65 kDa), GAD67 (67 kDa) and β-actin (42 kDa) antibodies were all
purchased from Abcam (Cambridge, MA, USA).
tartrate

salt,

minimum

98

%

TLC),

-amino

Nicotine ((-)-Nicotine hydrogen
butyric

acid

(GABA)

and

isobutylmethylxanthine (IBMX) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Ethanol was purchased from Fisher Scientific International (Fair Lawn, NJ, USA).
The lysis buffer used to extract proteins along with Pierce ECL western blotting substrate
were purchased from Thermo Scientific (Rockford, IL, USA).

Maintenance and chronic treatments of cultured cells
The immortalized human pancreatic duct epithelial cell line, HPDE6-C7, was
kindly provided to us by Dr. Tsao (Division of Cellular and Molecular Biology,
Department of Pathology, Ontario Cancer Institute/Princess Margaret Hospital,
University of Toronto, Toronto, ON, Canada). This cell line was clonally established
after transduction of the HPV16-E6E7 genes into primary cultures of pancreatic duct
epithelial cells. The human PDAC cell lines Panc-1 and BxPC-3 were purchased from
the American Type Culture Collection (Manassas, VA, USA). All cell lines were
authenticated at the beginning of the study by Research Animal Diagnostic Laboratory
(RADIL, Columbia, MO, USA) by species-specific PCR evaluation.
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Cell lines Panc-1 and BxPC-3 were maintained in DMEM and RPMI media
respectively and were both supplemented with 10 % Fetal Bovine Serum (FBS). HPDE6C7 cells were maintained in Keratinocyte Serum Free Medium (KSFM) supplemented
with 25 mg / 500 ml Bovine Pituitary Extract (BPE) and 2.5 µg / 500 ml Epidermal
Growth Factor (EGF) (GIBCO Invitrogen Corporation, Grand Island, NY, USA). All cell
lines were grown without any antibiotics in an atmosphere of 5 % CO2, 99 % relative
humidity and 37 o C.
Chronic treatment of cells in complete medium with ethanol (17 mM), GABA (30
M) or nicotine (1 M) was for 7 days. Fresh medium containing each drug was replaced
every 24 hours. In the untreated control cells, the medium was replaced every 24 hours.
Treatment groups were as follows:
Control: cells maintained for 7 days in complete medium without drugs;
Ethanol: cells treated with ethanol for 7 days;
Ethanol + GABA: cells treated simultaneously for 7 days with ethanol and GABA;
GABA: cells treated with GABA for 7 days;
Nicotine: cells treated with nicotine for 7 days;
Nicotine + ethanol: cells treated simultaneously with nicotine and ethanol.
The concentration (17 mM) of ethanol used is the equivalent of the legal blood
alcohol limit of 0.08 % in the USA. The concentration (30 M) is the equivalent of 21.7
mg/person/day and is within the recommended range of GABA as a nutritional
supplement. The concentration (1 M) of nicotine used is within the range of systemic
nicotine concentrations in moderate smokers.
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Assessment of cell proliferation by MTT assay
All three cell lines were seeded into 6-well plates at a density of 20,000 cells per
well (n= 5) in their respective complete media. Cells were then left untreated or treated
with ethanol, GABA or both for 7 days. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazoliumbromide) colorimetric assay (Sigma-Aldrich St Louis, MO, USA)
was then used for the assessment of cell proliferation following instructions provided by
the vendor. Absorbance of samples was read using an uQuant Bio-Tek Instrument ELISA
reader at a primary and reference wavelengths of 570 nm and 650 nm respectively.

Assessment of Cell migration by CytoSelect cell migration assay
The three cell lines were seeded onto the top chamber of polycarbonate membrane
filter inserts (8 µM pore size) in 6-well plates at a density of 20,000 cells per well in their
respective complete media. Using identical treatment groups as for the MTT assay
(above), a cell migration assay kit (Cell BioLabs, San Diego, CA, USA) was then used to
assess the migratory ability of these cells following the vendor’s instructions. Optical
density of cell samples was read at 560 nm using an uQuant Bio-Tek Instrument ELISA
reader.

Protein analyses of nAChR subunits and GAD isozymes by western blotting
The protein expression of nAChR subunits 3, 4, 5, and 7 and of GAD65 and
GAD67 was determined in cells from identical treatment groups as for the MTT and cell
migration assays to determine the effects of chronic ethanol and GABA. Expression
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levels of the 4 investigated nAChR subunits were additionally assessed in cells treated
with chronic nicotine or chronic nicotine plus ethanol.
Protein samples were prepared using lysis buffer (50-mmol / L Tris-HCl, 1 % NP40, 150-mmol / L NaCl, 1-mmol / L phenylmethysulfonylfluoride, 1-mmol / L Na3VO4,
1-mmol / L NaF, and 1 µg / mL of aprotinin, leupeptin, and pepstatin). After heat
denaturation, protein samples were electrophoresed, using 12 % SDS gels (Invitrogen)
and blotted onto membranes. The membranes were then blocked (5 % nonfat dry milk
solution) for one hour at room temperature. Membranes were then incubated overnight at
4 o C with the following primary antibodies: nAChR subunit α3, 4,  and 7, GAD65
and GAD67. The primary antibody β-actin was used as a loading control to ensure equal
loading of proteins. All membranes were then washed (0.5 % Tween 20 / TBS) and
incubated with their respective fluorescent secondary antibodies for two hours. Protein
bands were then visualized with enhanced chemiluminescence reagent (Pierce ECL
Western Blotting Detection Substrate). Following background subtraction, mean densities
of 2 rectangular areas of standard size per band from three independent westerns were
determined and mean values and standard deviation (n = 6) of protein expression were
calculated.

Assessment of responsiveness to ethanol by immunoassays for the detection of
neurotransmitters
Unpretreated cells from each cell line or cells pretreated for 7 days with 17 mM
ethanol were exposed to a range of ethanol concentrations (1 µM , 50 µM , 500 µM , 1
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mM, 17 mM and 35 mM) for 30 minutes prior to harvesting. The culture media,
containing the secreted stress neurotransmitters noradrenaline and adrenaline as well as
inhibitory GABA were then collected in 15 ml test tubes. The cells which contained
synthesized intracellular catecholamines and GABA were lysed and harvested into 1.5 ml
eppendorf tubes after a one time wash with warm 1X PBS. Total (secreted plus
intracellular) stress neurotransmitters and GABA of five samples per treatment group was
analyzed using 2-Cat and GABA-Research ELISA kits respectively following the
vendors’ recommendations. Absorbance of samples was read using an uQuant Bio-Tek
Instrument ELISA reader at 450 nm primary wavelength with a 630 nm reference
wavelength.

Quantitative assessment of accumulated intracellular cAMP levels
Chronic treatment groups for this assay were identical to those of the MTT and
cell migration assays (above). On the sixth day of treatment, cells were washed twice
with warm 1X PBS then incubated for 30 minutes with 1 mM of the phosphodiesterase
inhibitor isobutylmethylxanthine (IBMX) to prevent enzymatic breakdown of the cAMP
formed. Once the 30 minutes incubation was over, cells were washed with 1X PBS twice
then treated with 17 mM ethanol for 24 hours. The cells were then lysed and harvested
into 1.5 ml eppendorf tubes following the cAMP ELISA kit’s instructions. Quantitative
analyses of cAMP levels from five samples per treatment group were conducted using the
cAMP ELISA kit following the vendor’s recommendations. Absorbance of samples was
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read using an uQuant Bio-Tek Instrument ELISA reader at 405 nm primary wavelength
with a 550 nm reference wavelength.

Quantitative assessment of PKA activation and phosphorylation levels of signaling
proteins by immunoassay
Following identical chronic treatments as outlined for the MTT and cell migration
assays, the cells were lysed and harvested into 1.5 ml eppendorf tubes following ELISA
kits’ instructions. Quantitative analyses of PKA activity, Akt, CREB, Src, and ERK1/2
phosphorylation from five samples per treatment group were conducted using PKA
activity, Akt, CREB, c-Src, and ERK1/2 ELISA kits respectively following the vendors’
recommendations. Absorbance of samples was read using an uQuant Bio-Tek Instrument
ELISA reader at 450 nm primary wavelength with a 630 nm reference wavelength.

Analysis of neurotransmitter synthesis in response to chronic ethanol and nicotine
Cells from HPDE6-C7, BxPC-3 and Panc-1 were either untreated or treated with
1 µM nicotine, 17 mM ethanol or the combination of the two for 7 days in complete
media. Cells were then lysed and harvested into 1.5 ml eppendorf tubes after a one time
wash with warm 1X PBS. Quantitative analyses of intracellular GABA, adrenaline and
noradrenaline of five samples per treatment group were conducted using GABA Research
and 2-Cat ELISA kits respectively following the vendors’ recommendations. Absorbance
of samples was read using an uQuant Bio-Tek Instrument ELISA reader at 450 nm
primary wavelength with a 630 nm reference wavelength.
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Statistical analysis of data
Using GraphPad Instat software (GraphPad, San Diego, CA, USA), all data
presented in the figures as bar graphs were analyzed for statistically significant
differences among treatment groups by One Way ANOVA and Tukey-Kramer multiple
comparison test when data followed a normal distribution. Data that did not pass
normality tests were tested for significant differences by non-parametric Kruskal-Wallis
ANOVA followed by Dunn’s multiple comparison test. GraphPad Prism 5 software
(GraphPad, San Diego, CA, USA) was used to establish sigmoidal dose-response curves
and to calculate EC50 values by nonlinear regression analysis. Data of the immunoassays
are expressed as mean and + / - standard deviation of five samples per treatment group.
Using NIH ImageJ, two densitometric determinations per band were assessed in three
independent western blots (n=6) per protein and expressed as mean values and standard
deviations.

Results
Effects of chronic ethanol in the presence and absence of GABA on cell proliferation and
migration
Using an ethanol concentration (17 mM) equivalent to the legal blood alcohol
limit of 0.08 % in the USA, we found that all three investigated cell lines responded with
more than 2 fold increases (p < 0.0001) in the number of viable cells when exposed for 7
days to ethanol (Figure 1a). This response was significantly (p < 0.001) inhibited by
simultaneous exposure of the cells to GABA (Figure 1a) at a concentration (30 M)
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within the recommended daily dose of GABA as a nutritional supplement. In addition, 7day exposure to GABA significantly (p < 0.0001) decreased the number of viable cells in
the three cell lines not pre-treated with ethanol (Figure 1a). These findings were mirrorimaged by the results of cell migration assays that used identical treatment groups (Figure
1b), with more than 2.5 fold increase in migrated cells after 7-day treatment of the three
cell lines with ethanol (p < 0.0001) and significant (p < 0.0001) inhibition of this effect
by GABA.

Effects of chronic ethanol and GABA on the protein expression of nAChRs
We have previously shown that nAChRs expressing the subunits 3, 5 and 7
regulate the proliferation of PDAC cell lines Panc-1 and BxPC-3 as well as immortalized
pancreatic duct epithelial cells HPDE6-C7 by activating an autocrine stress
neurotransmitter loop [10]. In addition, we have shown that the 4-nAChR regulates the
synthesis and release of GABA in these cells and that GABA inhibits cell proliferation
and migration [10,14]. In order to further our understanding on the mechanisms involved
in the observed effects of chronic ethanol on cell proliferation and migration, we
therefore investigated the effects of chronic ethanol and GABA on the protein expression
of these nAChRs.

Our data show that chronic exposure to ethanol alone significantly

induced (p < 0.0001) protein expression of nAChR subunits α3 (4.5 fold), 4 (4 fold), 5
(5 fold) and α7 (5 fold). Simultaneous treatment of cells with GABA significantly (p <
0.0001) reduced these effects of ethanol (Figures 2a, b).
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Effects of chronic ethanol and GABA on the protein expression of glutamate
decarboxylase isozymes
The isozymes glutamate decarboxylase 65 (GAD65) and glutamate decarboxylase
67 (GAD67) catalyze the synthesis of GABA from glutamate [17]. We have previously
shown that the protein expression of these enzymes is suppressed resulting in reduced
synthesis of GABA when the 4-nAChR in PDAC cells or pancreatic duct epithelial cells
undergoes protein upregulation in response to desensitization by a single dose of nicotine
[10]. In analogy to these findings, our current data show significant reductions (p <
0.0001) in the protein expression of both GAD isozymes upon chronic ethanol exposure
and a reversal of this effect by treatment with GABA (Figures 3a, b).

Concentration-dependent effects of chronic ethanol on total GABA, adrenaline and
noradrenaline
In order to assess the functional significance of the observed changes in chronic
ethanol-induced protein expression of nAChRs and GADs on their effectors, we
measured total (intracellular plus secreted) levels of the inhibitory neurotransmitter
GABA and of the stress neurotransmitters noradrenaline and adrenaline in 7-day ethanol
pretreated versus non-pretreated cells exposed to a range of concentrations of ethanol (1
M - 35 mM). As shown in Figures 4a-c, chronic ethanol exposure reduced total GABA
at all concentrations tested and significantly (p < 0.l0001) decreased the EC50
concentrations for the reduction of GABA production in all three cell lines.
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By contrast, the concentration-dependent increases in total levels of the stress
neurotransmitters noradrenaline and adrenaline were significantly (p < 0.0001) enhanced
by 7-day pre-exposure to ethanol in all three cell lines (Figures 4d-i) and EC50 values of
ethanol for these increases were significantly (p < 0.0001) reduced.

Effects of chronic ethanol and GABA on intracellular accumulation of cAMP and PKA
activation
We have previously shown that nAChRs expressing subunits 3, 5 and 7
jointly regulate the synthesis and release of the stress neurotransmitters noradrenaline and
adrenaline in PDAC cells and pancreatic duct epithelial cells [10]. In turn, noradrenaline
and adrenaline are agonists for beta-adrenergic receptors [11,12] and increased
intracellular cAMP levels via activation of the stimulatory G-protein Gs in these cells,
resulted in the activation of PKA. [10]. We therefore measured intracellular cAMP levels
in the current experiments in order to assess the potential modulation of cAMP levels and
PKA activation by chronic ethanol. As Figures 5a and b show, chronic treatment of cells
with ethanol significantly (p < 0.0001) increased intracellular cAMP levels (3-4 folds) in
the three investigated cell lines while also significantly (p < 0.0001) increasing the levels
of activated PKA (2.8-3.4 folds). Simultaneous exposure of the cells to GABA during the
7-day ethanol pretreatment period significantly (p < 0.0001) reduced both of these
responses to ethanol (Figures 5a, b). In addition, chronic exposure of the cells to GABA
alone significantly (p < 0.0001) suppressed base levels of cAMP and activated PKA in
cells not pretreated with ethanol (Figures 5a, b).
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Effects of chronic ethanol in the presence and absence of GABA on the phosphorylation
of multiple signaling proteins
We have previously shown that activation of cAMP-dependent PKA results in the
phosphorylation of multiple signaling proteins involved in the regulation of proliferation,
angiogenesis, metastatic potential and apoptosis in PDAC cells [10,13-15]. We therefore
assessed the potential modulation in phosphorylation levels of these signaling proteins by
chronic ethanol in the presence and absence of simultaneous treatment with GABA. Our
results show that chronic exposure of normal pancreatic duct epithelia and both PDAC
cell lines to ethanol significantly induced (p < 0.0001) phosphorylation of ERK, CREB,
Akt and Src (Figures 6a, b). In analogy to our findings with cAMP and PKA,
simultaneous exposure of the cells to GABA during the ethanol pretreatment period
significantly (p < 0.0001) reduced each of these responses (Figures 6a, b).

Effects of chronic nicotine and ethanol on protein expression of nAChRs
Our laboratory has previously shown that nicotine stimulates the synthesis and
release of noradrenaline and adrenaline in PDAC cells and pancreatic duct epithelial cells
by binding to nAChRs expressing subunits α3, 5 and 7 [10] while suppressing the
synthesis and release of GABA by binding to the α4-nAChR [14]. We therefore assessed
potential cooperative effects of chronic ethanol with chronic nicotine on the protein
expression of the α3, 4, 5 and -nAChRs. Our data identify distinct cooperative
inductions of all four nAChRs when the three investigated cell lines were simultaneously
exposed for 7 days to nicotine and ethanol (Figures 7a, b), with significantly (p < 0.0001)
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higher levels of protein induction (p < 0.0001) in cells exposed to both agents than to
either agent alone.

Effects of ethanol and nicotine on the synthesis of GABA and stress neurotransmitters
In order to assess the functional significance of the cooperative protein induction
of nAChRs observed in the current study by chronic ethanol and nicotine (above), we
compared the intracellular levels of GABA, noradrenaline and adrenaline in cells exposed
to chronic nicotine, ethanol or both agents for 7 days. Our data show clear cooperative
effects (p < 0.0001) of nicotine and ethanol on the suppression of GABA observed with
either agent alone (Figure 8a). In addition, the stimulation of stress neurotransmitter
synthesis by nicotine or ethanol alone was significantly (p < 0.001) enhanced by
combination treatments with both agents (Figures 8b, c).

Discussion
Smoking and chronic alcohol consumption are established risk factors for
pancreatic cancer [1,18,19]. Heavy alcohol consumption is thought to facilitate pancreatic
cancer development by increasing the risk for diabetes and chronic pancreatitis which are
independent risk factors for this malignancy [8]. However, the mechanisms of how
smoking and chronic consumption of moderate amounts of alcohol jointly induce
pancreatic cancer are poorly understood.
It has been shown that nicotine addiction and alcohol dependence are highly
correlated [20,21] and that chronic nicotine-induced upregulation of nAChR proteins in
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brain cells is significantly enhanced by the simultaneous exposure to chronic ethanol
[21]. While nAChRs were initially thought to be uniquely expressed in the nervous
system, more recent studies have identified these receptors in the majority of mammalian
cells, including epithelia [22]. In accord with these reports, we have recently shown that
the stress neurotransmitters noradrenaline and adrenaline are synthesized and released by
normal pancreatic duct epithelia and PDAC cells in vitro when nicotine binds to nAChRs
expressing the subunits 3, 5, or 7 in these cells [10]. In accord with the established
function of noradrenaline and adrenaline as beta-adrenergic receptor agonists [11,12], a
single dose of nicotine thus increased cAMP and activated PKA, causing the
phosphorylation of multiple signaling

proteins

(p-ERK, p-CREB, p-Akt, p-Src)

frequently overexpressed in pancreatic cancer while also stimulating cell proliferation
[10]. Earlier studies by our laboratory have shown that exposure of immortalized
pancreatic duct epithelial cells to a single dose of ethanol at a concentration (17 mM)
equivalent to the legal blood alcohol limit (0.08 %) in the United States stimulates cell
proliferation by increasing intracellular cAMP levels, resulting in a significant induction
of activated PKA and PKA-dependent phosphorylation of CREB and ERK1/2 [23]. Our
current study shows, for the first time, that chronic exposure to this moderate ethanol
concentration significantly upregulates the protein expression of nAChRs 3, 4, 5 and
7 in pancreatic duct epithelial cells and PDAC cells. In analogy to observations in brain
cells [21], the induction of nAChR proteins was further enhanced by simultaneous
exposure of the cells to chronic nicotine. The observed significant increases in total
noradrenaline and adrenaline after chronic ethanol and associated significant decrease in
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EC50 values of ethanol required to stimulate the production of these neurotransmitters
indicate functional sensitization of nAChRs 3, 5 and 7. The resulting significant
inductions of activated PKA, CREB, ERK Akt and Src after chronic ethanol alone
additionally identifies these signaling proteins as the driving forces of chronic ethanolinduced cell proliferation and migration in the three investigated cell lines. While our
findings are in accord with reports from other laboratories that alcohol activates signaling
proteins such as ERK, JNK, PKC and Stat3 in liver cells [24-29], they suggest that these
proteins are downstream effectors of noradrenaline and adrenaline-induced betaadrenergic signaling.
By contrast, the observed upregulation of 4-nAChR protein upon chronic
exposure to ethanol represents a reaction to desensitization of this receptor as indicated
by the concentration-dependent suppression of GABA and associated reduction in
GAD65 and GAD67.
These findings are analogous to reports that chronic nicotine desensitizes the 4nAChR in the brain [30,31], and that the inhibitory effects of GABA on acute nicotineinduced proliferation of PDAC cells is mediated by the Gi-coupled GABA-B receptor
which inhibits the activation of adenylyl cyclase in these cells [14]. Similar to our
findings after a single dose of nicotine [10], chronic exposure to 30 µM GABA reversed
all chronic ethanol-induced cellular changes in the three investigated cell lines, including
the observed modulations in nAChRs expression and function, changes in stress
neurotransmitter and GABA levels and the resulting changes in signal transduction
cascades.
117

In summary, our findings suggest that changes in nAChRs expression and
function in the brain that are associated with nicotine addiction and alcohol dependence
are also induced by chronic ethanol and chronic nicotine in PDAC cells and pancreatic
duct epithelial cells where they cooperate to stimulate proliferation and migration.
Moreover, the strong inhibitory effects of GABA on the observed cellular responses to
chronic ethanol identify this neurotransmitter, which is widely used as a nutritional
supplement, as a promising agent for the prevention of PDAC in individuals at increased
risk due to chronic consumption of alcohol. In light of the fact that the GABA-B receptor
agonist baclofen has been identified as an effective therapeutic for alcohol dependence
[32,33], nutritional supplementation with GABA may not only have protective effects
against PDAC development but simultaneously reduce the craving of alcohol withdrawal
in dependent patients.
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Appendix

Figure 1.Cell proliferation (a) assessed by MTT assays and metastatic potential (b)
assessed by cell migration assays in HPDE6-C7, BxPC-3 and Panc-1 cells showing
stimulation of proliferation and migration upon ethanol exposure and a reversal of these
effects upon exposure to GABA. The columns represent means and + / - SD of 5 samples
per treatment group.
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Figure 2.Western blots assessing protein expression of α3, 4, 5 and 7-nAChRs in
cells treated with 17 mM ethanol, 30 µM GABA or both for 7 days. β-actin was used as
a control to ensure equal loading of proteins (a). The columns in figure (b) represent
means and + / - SD of two mean density readings per band from three independent
western blots (n = 6) expressed as fold changes in the expression of the nAChR subunits.
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Figure 3.Western blots assessing phosphorylation of GAD65 and GAD67 in HPDE6-C7,
BxPC-3 and Panc-1 cells treated with 17 mM ethanol, 30 µM GABA or the combination
of the two for 7 days. The house keeping protein β-actin was used as a control to ensure
equal loading of proteins (a). The columns in figure (b) represent means and + / - SD of
two mean density readings per band from three independent western blots (n = 6)
expressed as fold changes in protein phosphorylation.
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Figure 4.Total (secreted and intracellular) GABA (a-c), adrenaline (d-f) and
noradrenaline (g-i) levels in HPDE6-C7, BxPC-3 and Panc-1 cells treated with single
doses of ethanol from 1 µM to 35 mM for 30 minutes or pretreated with 17 mM ethanol
for 7 days and then exposed to identical concentrations of ethanol. Data points are mean
and + / - SD from five samples per treatment group.
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Figure 5.ELISA assays showing cAMP levels (a) and PKA activity (b) in HPDE6-C7,
BxPC-3 and Panc-1 cells treated with 17 mM ethanol, 30 µM GABA or the combination
of the two for 7 days. Data points are mean and + / - SD from five samples per treatment
group.
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Figure 6.ELISA assays showing phosphorylation of CREB and ERK (a) and Src and Akt
(b) in HPDE6-C7, BxPC-3 and Panc-1 cells treated with 17 mM ethanol, 30 µM GABA
or the combination of the two for 7 days. Data points are mean and + / - SD from five
samples per treatment group.
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Figure 7.Western blots assessing protein expression of α3, 4, 5 and 7-nAChRs in
cells treated with 1 µM nicotine, 17 mM ethanol or both for 7 days. β-actin was used as a
control to ensure equal loading of proteins (a). The columns in figure (b) represent means
and + / - SD of two mean density readings per band from three independent western blots
(n = 6) expressed as fold changes in the expression of the nAChR subunits.
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Figure 8.ELISA assays showing intracellular GABA (a), adrenaline (b) and
noradrenaline (c) levels in HPDE6-C7, BxPC-3 and Panc-1 cells treated with 1 µM
nicotine, 17 mM ethanol or the combination of both for 7 days. Data points are mean and
+ / - SD from five samples per treatment group.
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CHAPTER VI:
Conclusion
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Conclusion
Pancreatic cancer is the fourth leading cause of cancer deaths in western countries
with a five year survival rate of less than 5 % and a mortality rate near 100 % within the
first two years of diagnosis [1-4]. Epidemiological studies have shown that mortality
from pancreatic cancer has been increasing in developed countries between 1950s and 80.
Moreover, while mortality rate has been declining in men since 1970s, it has been on the
rise for women [5-8]. Several risk factors have been linked to pancreatic cancer
development including smoking, diabetes, chronic pancreatitis, chronic alcohol
consumption and family history [5,9-11]. Reports show that age, gender and race also
play a role in determining risk factor for this malignancy too. The risk of pancreatic
cancer increases with age with reports showing near 90 % of all patients being over the
age of 55 [10]. Moreover, the risk of pancreatic cancer is slightly higher in men than
women; and African Americans are more likely to have the disease than whites [10].
As with all other cancers, pancreatic cancer’s development and progression
involves the activation of oncogenes, the inactivation of tumor suppressor genes and the
deregulation of signaling proteins and their downstream pathways. Some of these
signaling proteins include EGFR, Akt, and NFκB [12]. It is the accumulation of several
induced and or inherited mutations in these genes that results in the development and
progression of pancreatic cancer and not just one mutation. While most of research in the
past focused on these signaling proteins and mutations that are involved in PDAC
development; little is done on receptors upstream of these signaling proteins and how
they may be involved in the regulation of pancreatic cancer.
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Recent studies by our laboratory have shown that upstream receptors such as
nicotinic acetylcholine receptors (nAChRs) and β-adrenergic receptors play vital role in
regulating pancreatic and lung cancer growth in vitro [13-16]. Activation of the
ionotropic nAChRs cause cellular changes that lead to neurotransmitter production
regulation. This nAChRs activation results in a systemic increase in the levels of
adrenaline

and

noradrenaline

and

a

reduction

in

GABA

synthesis.

These

neurotransmitters in turn act on G-protein coupled receptors such as β-adrenergic and
GABA-B receptors to regulate pancreatic cancer cells growth and migration via cAMP
dependent pathways [13,17-21].
In this project, we focused on studying the role of α3, 4, 5 and 7-nAChRs in
regulating growth and migration of normal pancreatic duct epithelial cells (HPDE6-C7)
and PDAC cells (BxPC-3 and Panc-1). We tested the effects of exposing these cells to
ethanol, nicotine and GABA and whether or not these agents modulate the sensitivity of
the nAChRs under investigation. Using western blots and assays for cAMP, GABA,
adrenaline, noradrenaline, PKA, CREB, ERK, Akt, Src, cell proliferation and migration,
our data show that these cells express an autocrine catecholamine loop that is jointly
regulated via α3, 5 and 7-nAChRs [15]. Moreover, our results show that these cells
express α4-nAChR which is involved in the regulation of the inhibitory neurotransmitter
GABA production and secretion [11,14,15,22-24].
For the first time, our data show that exposing these cells to nicotine or ethanol
results in the up-regulation of protein expression of α3, 4, 5 and 7-nAChRs in a
concentration dependent manner [15]. However, while this up-regulation in protein
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expression is associated with activation and sensitization of the α3, 5 and 7-nAChRs, the
α4-nAChR is desensitized [unpublished data]. Activation of α3, 5 and 7-nAChRs results
in cellular changes that lead to an increase in the synthesis and release of adrenaline and
noradrenaline. Both catecholamine act as agonist to β-ARs thereby activating these Gprotein coupled receptors. Activation of β-ARs then results in the activation of adenylyl
cyclase which leads to an increase in intracellular cAMP levels. This rise in cAMP level
results in the activation of PKA and other signaling pathways which ultimately increase
the phosphorylation of CREB, ERK, Akt and Src. All of these cellular changes associated
with adrenaline and noradrenaline ultimately stimulated cell growth and migration and
inhibited apoptosis [11,14,15,22-24].
The α4-nAChR on the other hand is involved in the regulation of GABA synthesis
and release. While binding of nicotine or ethanol to this receptor up-regulate its protein
expression, this binding results in desensitization of the receptor thereby reducing GABA
synthesis and release. This reduction in GABA level is critical to allow pancreatic cancer
progression for it acts as an inhibitory neurotransmitter inhibiting the signaling pathway.
Our data show that exposure of HPDE6-C7, BxPC-3 and Panc-1 cells to GABA causes a
significant reversal of nicotine- and ethanol- induced cell proliferation and migration
[24,25]. Binding of GABA to its G-protein coupled receptor GABA-B results in the
inhibition of adenylyl cyclase via the inhibitory G protein subunit of GABA-B receptor.
Inhibition of adenylyl cyclase therefore results in a reduction in cAMP levels thus
preventing cancer growth and migration [11,25].
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In summary, our project provides evidence for the first time that pancreatic cancer
development and progression is much more than just gene mutations. Receptors such as
nAChRs and neurotransmitters associated with these receptors play vital role in
regulating pancreatic cancer growth. Moreover, while our data show promising results of
GABA as a potential therapeutic option in vitro, much more research is needed to study
its effects in vivo. Statistics of pancreatic cancer are still on the rise and we can only hope
for research to help bring those stats down.

134

References
1. Duell, E.J. (2012) Epidemiology and potential mechanisms of tobacco
smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog,
51, 40-52.
2. Jemal, A., et al. (2010) Cancer statistics, 2010. CA Cancer J Clin, 60, 277300.
3. Siegel, R., et al. (2012) Cancer treatment and survivorship statistics, 2012. CA
Cancer J Clin.
4. Siegel, R., et al. (2012) Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
5. Bosetti, C., et al. (2012) Pancreatic cancer: overview of descriptive
epidemiology. Mol Carcinog, 51, 3-13.
6. Edwards, B.K., et al. (2010) Annual report to the nation on the status of
cancer, 1975-2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce future rates.
Cancer, 116, 544-73.
7. La Vecchia, C., et al. (2010) Cancer mortality in Europe, 2000-2004, and an
overview of trends since 1975. Ann Oncol, 21, 1323-60.
8. Levi, F., et al. (2003) Pancreatic cancer mortality in Europe: the leveling of an
epidemic. Pancreas, 27, 139-42.
9. Bracci, P.M. (2012) Obesity and pancreatic cancer: overview of
epidemiologic evidence and biologic mechanisms. Mol Carcinog, 51, 53-63.
10. American Cancer Society. (2012) Pancreatic Cancer
http://www.cancer.org/pancreaticcancer/overviewguide/index.

Overview.

11. Askari, M.D., et al. (2006) Ethanol and the tobacco-specific carcinogen,
NNK, contribute to signaling in immortalized human pancreatic duct
epithelial cells. Pancreas, 33, 53-62.
12. Iovanna, J., et al. (2012) Current knowledge on pancreatic cancer. Front
Oncol, 2, 6.
13. Al-Wadei, H.A., et al. (2010) Chronic exposure to estrogen and the tobacco
carcinogen NNK cooperatively modulates nicotinic receptors in small airway
epithelial cells. Lung Cancer, 69, 33-9.
135

14. Al-Wadei, H.A., et al. (2009) Nicotine stimulates pancreatic cancer xenografts
by systemic increase in stress neurotransmitters and suppression of the
inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis, 30,
506-11.
15. Al-Wadei, M.H., et al. (2011) Pancreatic cancer cells and normal pancreatic
duct epithelial cells express an autocrine catecholamine loop that is activated
by nicotinic acetylcholine receptors alpha3, alpha5, and alpha7. Mol Cancer
Res.
16. Arredondo, J., et al. (2006) Nicotinic receptors mediate tumorigenic action of
tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer
Biol Ther, 5, 511-7.
17. Askari, M.D., et al. (2005) The tobacco-specific carcinogen, 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of
immortalized human pancreatic duct epithelia through beta-adrenergic
transactivation of EGF receptors. J Cancer Res Clin Oncol, 131, 639-48.
18. Benowitz, N.L. (2003) Cigarette smoking and cardiovascular disease:
pathophysiology and implications for treatment. Prog Cardiovasc Dis, 46, 91111.
19. Benowitz, N.L. (2008) Neurobiology of nicotine addiction: implications for
smoking cessation treatment. Am J Med, 121, S3-10.
20. Schuller, H.M. (2009) Is cancer triggered by altered signalling of nicotinic
acetylcholine receptors? Nat Rev Cancer, 9, 195-205.
21. Weddle, D.L., et al. (2001) Beta-adrenergic growth regulation of human
cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis,
22, 473-9.
22. Al-Wadei, H.A., et al. (2009) Prevention of pancreatic cancer by the betablocker propranolol. Anticancer Drugs, 20, 477-82.
23. Al-Wadei, H.A., et al. (2011) Gamma-Amino Butyric Acid Inhibits the
Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small
Cell Lung Carcinoma. Curr Cancer Drug Targets.
24. Al-Wadei, H.A., et al. (2011) GABA (gamma-aminobutyric acid), a nonprotein amino acid counters the beta-adrenergic cascade-activated oncogenic
136

signaling in pancreatic cancer: A review of experimental evidence. Mol Nutr
Food Res, 55, 1745-58.
25. Schuller, H.M., et al. (2008) GABA B receptor is a novel drug target for
pancreatic cancer. Cancer, 112, 767-78.

137

VITA
Mohammed Hussein Abdulhadi Al-Wadei was born on March 10th, 1989 in AlAhsa city, Saudi Arabia. Four years later, he moved to Sana’a, Yemen where he received
his elementary and part of his secondary (middle) education. On August 2011, he moved
to the U.S along with his family where his father would obtain his doctoral degree in
Comparative and Experimental Medicine. There, he finished his secondary education and
obtained a diploma in science from West High School of Knoxville in December 2005
ranking in the top 1 % of his class.
In January 2006, Mohammed enrolled at the University of Tennessee where he
majored in Biochemistry Cellular and Molecular Biology. Besides receiving several
honors and awards, his name was listed in the Dean’s list of top undergraduate students
every year during his undergraduate education. In May 2010, he graduated with a
bachelor degree in science with an excellent grade point average ranking in the top 5 %.
In the summer of 2010, Mohammed was admitted as a Ph.D. student in
Comparative and Experimental Medicine at the University of Tennessee under the
supervision of Dr. Hildegard M. Schuller. Besides participating in several local and
national symposiums and conferences, he received an award of research excellence in the
graduate students’ category in summer of 2011 in the Comparative and Experimental
Medicine and Public Health Symposium at the University of Tennessee. On August 2012,
he received his doctoral degree with a dissertation entitled “Growth Regulation of
Pancreatic Cancer Cells and Their Normal Cells of Origin by Nicotinic Acetylcholine
Receptors.”
138

